WO1992005829A1 - Temporary stent and methods for use and manufacture - Google Patents

Temporary stent and methods for use and manufacture Download PDF

Info

Publication number
WO1992005829A1
WO1992005829A1 PCT/US1991/007570 US9107570W WO9205829A1 WO 1992005829 A1 WO1992005829 A1 WO 1992005829A1 US 9107570 W US9107570 W US 9107570W WO 9205829 A1 WO9205829 A1 WO 9205829A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
stent portion
distal end
elongate member
region
Prior art date
Application number
PCT/US1991/007570
Other languages
French (fr)
Inventor
Lloyd Willard
Dale F. Schmaltz
Original Assignee
Scimed Life Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems, Inc. filed Critical Scimed Life Systems, Inc.
Priority to JP4500711A priority Critical patent/JPH06502333A/en
Publication of WO1992005829A1 publication Critical patent/WO1992005829A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00Dilators with or without means for introducing media, e.g. remedies
    • A61M29/02Dilators made of swellable material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30667Features concerning an interaction with the environment or a particular use of the prosthesis
    • A61F2002/30672Features concerning an interaction with the environment or a particular use of the prosthesis temporary
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30667Features concerning an interaction with the environment or a particular use of the prosthesis
    • A61F2002/30677Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0059Additional features; Implant or prostheses properties not otherwise provided for temporary
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body

Definitions

  • This invention relates to devices known as stents which provide support to a vessel, such as a blood vessel, and in particular to stents that are both temporary and removable.
  • Obstructive coronary artery disease is one of most serious health problems facing our society today. This disease is the result of the deposit of fatty substances on the interior surface of the walls of the arteries. The build up or lesion of such deposits results in a narrowing of the diameter of the artery which restricts the blood flow through the artery. This condition wherein the artery is narrowed is known as stenosis.
  • the lesion may form in any part of the artery and in some instances the deposits may form at the intersection between two arteries, that is, where the section where the two arteries form a generally "Y" configuration (e.g. bifurcate, trifurcate, and so on) .
  • Angioplasty is a procedure in which a balloon is positioned on the inside of the artery at the site of the lesion and expanded in order to compress the materials at the lesion and thus open the restricted area in the artery.
  • an elastic balloon is attached to one end of a small diameter flexible catheter which includes means for inflating the balloon from the other end of the catheter. The catheter is maneuvered through the patient's vessels to the site of the lesion with the balloon in uninflated form. When the uninflated balloon is properly positioned at the lesion, the balloon is then inflated to dilatate the restricted area.
  • Atherectomy is a procedure in which a small cutting tool is attached to the end of a small diameter flexible catheter and maneuvered through the patient's arterial system to the site of the lesion in the diseased artery. When the cutting tool is properly positioned, the tool is used to cut and remove the deposits from the surface of the diseased artery.
  • a stent is a device which is used to hold or maintain the diameter of the artery or vessel.
  • stents are available in the art, these are generally of the type intended for permanent use. This type of permanent stent is implanted in a patient's vascular system and remains in place after the procedure or operation. Such permanent types of stents are shown, for example, in U.S. Patent Nos. 4,913,141, 4,878,906, 4,856,516 and 4,820,298. These permanent type of stents may not always be desired for the situations described above. First, it may be unnecessary and even undesirable to install a permanent device when only temporary support is needed. Further, these permanent type of stents may require a relatively complicated procedure to install. Further, use of permanent stents results in extended hospital observation and recovery time.
  • a complement of drug therapies are required in order to offset the bioreaction resulting in thrombus formation or smooth muscle cell proliferation on the stent surface.
  • These drug therapies may be required for a significant period of time until new normal endothelial cells have formed. In situations such as a "bail-out it is desirable for the physician to have the ability to quickly maneuver the stent to the desired location and quickly and easily place the stent in its operating mode.
  • a temporary stent on the other hand may be particularly useful in situations where it is intended to be used in the patient only for several minutes or days and then removed. For example, use of a temporary stent in a bail-out situation will enable the physician to defer a more complicated procedure until a patient's condition is more stable, or in some cases eliminate further procedures by resecuring the vessel geometry which allows near normal blood flow.
  • a temporary stent be relatively easy to both install and remove. Since the temporary stent remains in place for a period of time, it is important that the temporary stent not block the flow of blood through the vessel. That is, the blood must be able to travel through the vessel in which the temporary stent is installed while the stent is in place. Further, since the lesions often occur at the intersection of two vessels, in order to position the temporary stent it is may be necessary to place the stent across the intersection. Therefore, it is critical that the stent provide a flow path radially as well as axially or longitudinally. This arrangement will allow blood flow to both of the intersecting arteries.
  • a temporary stent Since the temporary stent will be removed after a period of time, it is important that the temporary stent not permanently adhere to the inner walls of the vessel in which it is placed. In addition, a temporary stent should have no tendency, or only a minimal tendency, to cause clotting.
  • the present invention relates to a temporary stent for supporting a region of a vessel in a body comprising a stent portion and an actuator portion and methods for the use and manufacture thereof.
  • the stent portion is comprised of an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel.
  • the stent portion also includes perfusable end portions connected to and forming ends of the vessel supporting portion and adapted to allow fluid flow therethrough.
  • the actuator portion includes a proximal end extending out of the body and a distal end connected to the stent portion and operable by manipulation at the proximal end thereof to configure the support portion into a reduced size and an expanded size.
  • the temporary stent may be positioned in the desired region in its contracted form and then expanded to provide the desired support to the vessel.
  • the temporary stent may be left in place for a selected period of time and then be easily removed by the physician.
  • the arrangement of the present invention allows the stent to remain in place without significantly interfering with the flow of fluids through the vessel.
  • the stent is attached to the distal end of a flexible catheter and a fluid conduit is provided which extends from the proximal end of the catheter to a point close to the stent.
  • This fluid conduit provides a channel through which medicine may be introduced to an area near to the stent.
  • Angiographic fluids, such as dyes, injected into the blood flow in the vessel allow imaging of the vessel and blood as it passes through the stent.
  • Figure 1 depicts a first preferred embodiment of the present invention.
  • Figure 2 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in a reduced contracted configuration.
  • Figure 3 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in an expanded configuration.
  • Figure 4 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
  • Figure 5 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
  • Figure 6 depicts a distal portion of another embodiment of the present invention.
  • Figure 7 depicts a distal portion of another embodiment of the present invention in a contracted configuration.
  • Figure 8 depicts the distal portion of the embodiment shown in Figure 7 in an expanded configuration.
  • Figure 9 depicts another embodiment of the present invention.
  • Figure 10 is a cross section of an embodiment of a wire component along lines 10-10' of Figure 2.
  • FIG. l there is depicted a first embodiment of the present invention.
  • the embodiment of Figure l is a temporary stent 10 which can be placed in the vascular system of a patient after a procedure such as angioplasty, atherectomy or other interventional therapies.
  • the temporary stent 10 is particularly useful in procedures involving blood vessels, it may be used in other fluid carrying vessels in the patient's body.
  • the term "vascular system” refers to a vessel for conveying body fluids.
  • the temporary stent 10 is intended for placement in a vascular system for limited durations of time from several minutes to up to several days.
  • the temporary stent 10 includes a perfusable stent portion 14 and an actuator portion 18.
  • the stent portion 14 is connected to a distal end 20 of the actuator portion 18.
  • the actuator portion 18 extends proxi ally from its connection to the stent portion 14 through the vascular system and out of the body of the patient.
  • the proximal end 22 of the actuator portion 18 which extends out the body of the patient is connected to one or more and preferably two manifolds 24 and 26.
  • the stent portion 14 is expandable and contractable so that it can be positioned in the vascular system at the specific location where needed and then expanded to an appropriate size (i.e. approximately the same diameter as the vessel in the region where placed) thus supporting that vascular region.
  • an appropriate size i.e. approximately the same diameter as the vessel in the region where placed
  • the stent portion 14 When in its expanded configuration, provides support to the vascular walls thereby preventing constriction of the vascular region in which it is located and maintaining the vascular lumen open.
  • the construction and materials for the stent portion 14 should provide that the stent be perfusable. i.e. it should allow blood flow therethrough both in the axial direction of the vessel to maintain blood flow through the region in which the stent is located as well as in the radial direction so that any vessels that branch off from the region of the vessel into which the stent portion is placed will not be occluded.
  • the stent portion 14 should be relatively transparent to blood flow in order to maintain vascular function while at the same time providing support for the vessel walls in the region where it is located.
  • Expansion and contraction of the stent portion 14 inside the patient's body may be accomplished from outside of the patient's body by means of manipulation of the actuator portion 18 from the proximal end 22 thereof which is located outside the patient's body.
  • the actuator portion 18 comprises a first elongate member 28 that connects to a proximal end 30 of the stent portion 14 and a second elongate member 32 that connects to the distal end 34 of the stent portion 14. Relative movement of the first elongate member 28 and the second elongate member 32 causes expansion and contraction of the stent portion 14, as explained in more detail below.
  • the distal end 20 of the actuator portion 18 remains in place in the body during the period of time that the stent portion 14 is in place in the vascular system and during this time the proximal end 22 of the actuator portion 18 extends out of the patient's body.
  • the first elongate member 28 terminates at a manifold 24 and the second elongate member 32 terminates at the manifold 26.
  • these manifolds include hemostatic valves and Y-connecters for administering fluids, such as medicines through these manifolds, as described below.
  • the stent portion 14 is comprised of a braid made of a plurality of helically wound wires forming an elongated hollow tube. Typically, half of the wires forming this tube will be wound in one helical direction and the other half will be wound in the opposite helical direction and interwoven with the first half. Braiding of these wires provides for an elongated, expandable hollow tube that can, in a preferred embodiment, increase in diameter when the ends of the hollow tube are moved closer relative to each other and decrease in diameter when the ends of the hollow tube are move apart relative to each other. The ratio by which the stent portion expands depends upon the spacing between adjacent wires that make up the braid as well as the cross sectional dimensions of each of the individual wires.
  • the stent portion 14 may be provided in a wide range of sizes and stiffnesses to meet the requirements for use with different lesions or flaps in a patient's vascular system.
  • the stent portion 14 is constructed to be flexible enough to traverse its way to the region of the vascular system where it is to be located and expanded to provide support for the region of the vascular system, such as the site of previous angioplasty or other treatment.
  • the stent portion 14 terminates in a distal end 34.
  • the second (or inner) elongate member 32 is connected to the distal end 34 of the stent portion 14, as explained below.
  • the second elongate member 32 extends proximally from its connection to the distal end 34 of the stent portion 14, through the hollow tube of the stent portion 14, and through an inner lumen of the first elongate member 28 to the proximal end thereof.
  • relative movement between the first elongate member 28 and the second elongate member 32 causes corresponding movement of the proximal end 30 and distal end 34 of the stent portion 14 thus in turn causing expansion or contraction of the diameter of the elongate hollow tube of the stent portion 14.
  • the temporary stent 10 is depicted in its constricted configuration with the elongate hollow tube of the stent portion 14 having a reduced diameter.
  • the second elongate member 32 extends distally from the first elongate member 28 so that the length of the stent portion 14 is LI.
  • the second elongate member 32 is positioned at a location more proximate relative to the first elongate member 28 than in Figure 2 (i.e., in the direction of arrow 35) causing the length of the stent portion 14 to be equal to L2 (L2 being less than LI) .
  • the second elongate member 32 causes the proximal and distal ends 30 and 34, respectively, of the stent portion 14 to move relatively closer together thus causing the diameter of the elongate hollow tube of the stent portion 14 to expand to a dimension suitable for supporting a region of the vascular system.
  • the temporary stent 10 can be maintained in this expanded configuration by fixing the proximal ends of the first and second elongate members 28 and 32 for the duration of the time that the temporary stent 10 is maintained in the vascular system.
  • first elongate member 28 and the second elongate member 32 may be attached to the proximal ends of the first elongate member 28 and the second elongate member 32 at the manifolds 24 and 26. These two elongate members can be later disengaged from each other to permit reducing the diameter of the temporary stent 10 for removal thereof from the body.
  • one or more radiopaque markers may be located on a distal region of the stent, for example on a distal region of the second elongate member 32. These markers may be bands of radiopaque materials such as platinum, tantalum, gold, tungsten or a tungsten-iridium alloy.
  • the second elongate member 32 is an inner catheter 44.
  • the distal end 34 of the stent portion 14 surrounds an outside wall of the inner catheter 44.
  • a collar 46 surrounds and affixes the distal ends of the wires that make up the braid of the stent portion 14 to the distal end of the inner catheter 44 (i.e. first elongate member 32).
  • the collar 46 may be made of a balloon tubing polyolefin or other ultra-thin wall polymers.
  • the collar 46 may be heated to fuse to the outer wall of the inner catheter 44 or connected thereto by an adhesive or other suitable means.
  • the distal end 34 of the stent portion 14 may be securely fixed to the inner catheter 44 suitably for the duration of the use of the temporary stent 10.
  • a distal tip 48 of the temporary stent 10 is formed of an extension of the inner catheter 44 distally past the collar 46. This extension may be approximately 0.25 cm.
  • the inner catheter 44 has a lumen 50 therewithin that communicates with an opening 52 at the distal tip 48. Referring to Figure 5, there is a longitudinal sectional view depicting a portion of the proximal end 30 of the stent portion 14 and the actuator portion 18 and specifically the connection of the proximal end 30 of the stent portion 14 to the first elongate member 28 of the actuator portion 18.
  • the first elongate member 28 is an outer catheter 54.
  • the outer catheter 54 includes an inner tubular layer 56 and an outer tubular layer 58 that is concentric with the inner tubular layer 56.
  • the outer diameter of the outer catheter 54 would be approximately close to, but may be slightly larger than, the contracted diameter of the stent portion 14.
  • the outer catheter 54 may be approximately 1.35 mm, and for peripheral applications the outer catheter 54 may have a diameter of approximately 2.10 mm.
  • the length of the outer catheter 54 could be made to various sizes to be suitable for different treatment sites. For coronary applications, the length of the outer catheter 54 would be approximately 175 cm, for example.
  • the proximal end 30 of the stent portion 14 is secured between the inner and outer concentric tubular layers 56 and 58 by extending the wires of the braid proximally between these concentric layers.
  • the concentric tubular layers 56 and 58 and the wires of the braid of the stent portion 14 may be bonded together by an appropriate adhesive or by heating. A frictional fit may also be suitable.
  • the wires of the braid extend the entire length proximally to the proximal end of the first elongate member 28.
  • the wires of the braid of the stent portion 14 may extend only a short distance or an intermediate distance proximally between the concentric tubular layers 56 and 58.
  • the inner tubular layer 56 terminates a distance proximally from the distal end of the outer tubular layer 58.
  • the necked down portion 60 of the outer catheter 54 may be approximately 3 to 30 cm in length.
  • proximal 30 and distal 34 ends of the stent portion 14 will assume a proximal and distal truncated conical profile regions 62 and 64.
  • These truncated conical profile regions 62 and 64 taper from a narrow dimension where the wire braid is affixed to the actuator portion 18 proximally and distally (i.e., first and second elongate members 28 and 32) up to the expanded diameter of the stent portion 14.
  • These regions 62 and 64 may be linearly tapered, but a non-linear taper may also be provided. The type of taper depends upon the type of braiding method used.
  • the distal tapered region 64 may not correspond exactly in size or slope to the proximal tapered region 62.
  • the braiding method used preferably provides for relatively large distances between adjacent wires to provide correspondingly large openings around and through the plurality of wires at the ends of the stent portion 14 to facilitate blood flow therethrough.
  • the temporary stent 10 may be positioned in the vascular region over a guidewire 70 through the lumen 50 of the inner catheter 44.
  • the guidewire 70 may be a standard guidewire suitable for the region of the vascular system into which the stent will be located. According to this embodiment, the guidewire 70 is positioned in the vascular system across the region where it is desired to install the temporary stent 10.
  • the guidewire 70 may be positioned by standard procedures.
  • the diameter of the lumen 50 of the inner catheter 44 is of a sufficient size to allow the stent portion 14 to be advanced in the vascular system over the guidewire 70.
  • the temporary stent 10 including the stent portion 14 and the distal end of the actuator portion 18 is advanced over the guidewire 70.
  • the lumen 50 of the inner catheter may be compatible with 0.014, 0.016, or 0.018 guidewires for coronary applications and with up to 0.038 guidewires for peripheral applications.
  • the temporary stent 10 could be located in the vascular region by guiding it through a separate catheter (e.g. a delivery catheter) large enough to contain the temporary stent 10 in its contracted configuration.
  • a separate catheter e.g. a delivery catheter
  • the stent portion 14 of this embodiment is expandable from a size of approximately 1.25 mm or less to up to approximately 4.0 mm.
  • the stent portion 14 of the temporary stent 10 may have a contracted diameter of less than approximately 2.0 mm and an expanded diameter of up to approximately 6.0 mm.
  • the length of the stent portion 14 is approximately 2.5 to 5 cm when in its most extended position (i.e. when the diameter of the stent portion 14 is in its contracted configuration) .
  • the length of the stent portion is somewhat less, e.g. approximately 1.5 to 3.5 cm.
  • fluids such as medicines may be introduced to the vascular system via the lumen 50 of the inner catheter 44 as well as through a lumen 72 of the outer catheter 54 around the inner catheter 44.
  • Medicines introduced via the inner catheter 44 will enter the vascular system at the distal end 48 of the stent portion 14 via opening 52.
  • sufficient space is provided in the lumen 72 of the outer catheter 54 around the inner catheter 44, so that a second passageway for the introduction of fluids such as medicines to the vascular system is also provided.
  • Medicines introduced via the lumen 72 of the outer catheter 54 will enter the vascular system at the proximal end 30 of the stent portion 14.
  • the attending physician has the choice of selecting the point of entry for medicines administered e.g., either upstream or downstream of the stent portion 14.
  • medicines such as non- thrombogenic drugs, can be administered upstream of the stent portion 14 where they would be most effective in the region of the stent portion 14.
  • the stent portion 14 is first contracted from its expanded configuration to a reduced configuration. To do this, the first elongate member 28 is moved proximally relative to the second elongate member 32 thereby drawing down the diameter of the stent portion 14 to a size to facilitate removal from the vascular system.
  • the wires of the stent portion 14 should smoothly peel from the vessel wall causing no or only minimal trauma. It is not necessary that the stent portion 14 be drawn down entirely to its completely reduced size. It is sufficient that the stent portion 14 is drawn down sufficiently to disengage the inner walls of the vascular region and to be of a size sufficiently small to traverse the vascular system out of the body. Then, after the stent portion 14 is in a reduced configuration it may be removed from the vascular system by drawing it out by means of the attached actuator portion 18.
  • the inner catheter 44 is comprised of a .021 X .028 inch polymeric tubing.
  • the tubing used may be a blended Poly-Ethylene comprised of High Density Polyethylene (HDPE) and Low Density Poly- Ethylene (LDPE) .
  • the inner catheter 44 may also be constructed of Poly-Propylene, TPFE teflon or TPX.
  • TPX is a trade name for the Methyl Methylpentene Copolymer manufactured by Mitsui Plastics, Inc. and distributed from White Plains, NY).
  • TPX is a trade name for the Methyl Methylpentene Copolymer manufactured by Mitsui Plastics, Inc. and distributed from White Plains, NY).
  • the use of TPX enables the stent to be used for ultrasound imaging of the vessel that is being supported by the stent because the acoustical properties of this polymer match to that of water and blood.
  • the inner tubular layer 56 may be constructed of the same combination of polymers described for the inner catheter 44.
  • the inner tubular layer 56 may terminates 3 to 30 cm proximally from the proximal end 30 of the stent portion 14. This provides for the ability to reduce the section of the outer layer 58 by way of a drawing (or necking operation) on the outer layer 58.
  • the preferred size for this inner tubular layer 56 of the first elongate member 28 is .033 X .039 inch.
  • the outer tubular layer 58 of the first elongate member 28 may also be constructed of blended HDPE-LDPE, or polypropylene.
  • the dimensions of the outer tubular layer 58 of the preferred embodiment may be .045 X .053 inches in the proximal section of the first elongate member 28 extending from the manifold 24 at the proximal end to approximately 3 to 30 cm from the proximal portion 30 of the stent portion 14. From this point distally, the outer tubular layer 58 may be preferable reduced to .039 X .045. This may be accomplished by a necking or drawing operation which is achieved by pulling the tube through a heated die and allowing the plastic to reflow.
  • the inner dimension of the outer tubular layer 58 as well as the distal necked region 60 is adjusted accordingly for a 3.0 or 3.5 mm stent as may be seen to accommodate the wire of greater thickness. Since the outer diameter of the inner tubular layer 58 is .039 inches the placement of the braid on top of this layer, i.e. in the lumen 72, adds a factor of four times the wire thickness to the profile of the device prior to installation of the outer tubular layer 58. It is therefore apparent that the inner diameter of the outer tubular layer 58 should be adjusted to a minimum of .047 inches for the 3.0 mm and 3.5 mm versions. The tubing dimension may then be adjusted for the outer tubular layer to .055.
  • wire of rectangular cross section (herein referred to as flat wire) are utilized.
  • the preferable size wire to make a 2.0 mm stent is .003 inches.
  • wire of a size of .003 to .0035 may be used.
  • wire of either .0035 or .0040 should be used. From this, the advantage of using flat wire becomes apparent.
  • added thickness due to the braid is detailed below.
  • the braiding operation uses flat wire.
  • a 2.0 mm stent is constructed with a braid mesh network using stainless steel wire of rectangular cross section with a thickness of .001 inch X .004 inch.
  • the wire used is stainless steel wire with a rectangular cross section of .0015 inches in thickness and .004 inch in width.
  • the 3 mm stent is constructed with a stainless steel wire of rectangular cross section with .002 inch thickness and .004 inch width.
  • a 3.5 mm stent is constructed with either a .002 inch thickness and.004 inch width, or a .002 inch thickness and .005 inch to .007 inch width.
  • the wires that are used for the braid of the stent portion can be fragile due to their small size and care should be exercised in the manufacturing process. This is particularly true for the smaller wires such as the .003 inch round or the .0008 to .0015 thickness flat wires.
  • the wire used in each of the aforementioned braiding operations is 304 stainless steel in a spring temper.
  • the specific wire used is the Hyten (TM) wire available from Fort Wayne Metals of Fort Wayne, Indiana.
  • any one or more or and preferably 2, 3, or 4 of the 8 wires that comprise the braid may be made of an alloy of 92% platinum and 8% tungsten for the purpose of providing radiopacity. These alloys may are commercially available from a number of sources, such as Sigmund Cohn Corp. of Mount Vernon, N.Y., or California Fine Wire of Grover City, California.
  • the braiding process of the present invention requires modification of a commercially available braiding machine to achieve the desired consistency and braid density.
  • the braid pattern is composed of 8 wires.
  • Braiding machines range in size from 16 carriers to 100 carriers.
  • the braiding machine used for the manufacture of the stent described herein is a modified KoKobun SL-4-16 braider available from Wardwell Braiding Machine Co. of Rhode Island, NY. This same company also manufacturers a series of braiders under the New England Butt trade name.
  • the braiders may be manufactured to accommodate 4, 6, 8, 10, 12, 16, or 24 bobbins in the machine groups defined as NE Butt #1, #2, or the B-ll-8.
  • Machine modifications include the removal of 8 of the 16 carriages, as well as the installation of ultra light tensioning springs on the braider carriages.
  • tent angle i.e. the angle with which the wires approach the central core on which the braid is being installed
  • the wire normally is free to float up and down as the braiding wire position and rate equilibrate on the central core.
  • the wire may tend to get caught on other wires which are being applied in the opposing direction.
  • the wires then would get flipped over every few linear inches of braid therefore making the segment unusable or incorporatable within the catheter.
  • This problem may be eliminated by providing an angled guide made of a low friction material such as teflon and containing the angle for which the desired tent angle should be guided.
  • the size and density of the stent is controlled by three variables: the size of the central core to which the braid is being applied; the rate of advancement of the central core through the braid region; and the angular velocity of the braiding carriages. These variables relative to each other determine the "pick" (number of wire group intersections per inch) density of the braid pattern. These variables also determine the size of the stent that will be manufactured. In the preferred embodiment, a 2.0 mm stent is made on a central core with a size of .050 inches and a density of 10 per inch. When removed from the core the stent will spring from the I.D.
  • the degree for which the stent expands when removed from the core depends on the pick density during the braiding operation.
  • the table below outlines the preferred expanded pick densities for the individual stent configurations.
  • the braiding machine used must be modified so that the take up velocity of the central core and the radial velocity may be adjusted very precisely to achieve the exact density required. Due to the addition of the guide, as explained above, the density of the braid will not be allowed to assume its own pattern density by climbing up and down the central core, but instead will assume the required density. pic distance when expanded 1.8 to 3.6 mm 1.8 to 3.6 mm 1.8 to 3.6 mm 1.8 to 3.6 mm 1.8 to 3.6 mm mm 1.8 to 3.6 mm mm
  • the desired density in this preferred embodiment is obtained by placing the bridges 1.8 to 3.6 mm apart.
  • an feature of the temporary stent is that it is highly perfusable. This is accomplished in part by minimizing the density of metal within the vessel which may restrict the blood flow both though the ends of the stent and also radially from the sides of the stent. This is important because frequently side branches to the blood vessel are contained in the stent region and flow must exit the stent to keep these side branches perfused. The area or size of the stent should be minimized to maximize perfusion while maintaining sufficient structural support for a flap or other damaged part of the vessel.
  • the stent portion should not only be perfusable to allow blood flow therethrough, but should also minimize surfaces upon which a thrombus might form.
  • the vascular system is very active with respect to clot formation once a vessel has been damaged or subjected to other trauma such as during an angioplasty. Any device that is installed for more than a few minutes is susceptible to clot formation. Because in some embodiments, the temporary stent may be used for up to several days, it should also provide for minimization of clot formation.
  • the wires of the braid in the preferred embodiment are made of rectangular wires braided into a 4, or 8 wire braid and rectangular wire may, by reason of the manufacturing processes, have edges that are very and/or sharp.
  • the wire is made by initially drawing it through a die in order to form the specific size that is desired.
  • the temper of the spring may be modified by the cold work that is being induced into the wire from the forceful shaping of the wire.
  • the spring tempers are being achieved with pressures which are substantially greater than 300,000 psi. This spring temper is very desirable from the standpoint of imparting desirable properties to the stent.
  • the stent must be resilient to return from its initial contracted configuration to the full expanded state with only a minimal application of external force.
  • the temper is relevant to the fabrication process and ultimately to the product performance.
  • edges formed on the flat wire are rounded off.
  • the preferred method used to radius the corners of the flat wire is electropolishing which removes edges or protrusions of the material and passivates the metal without altering the bulk properties of the metal.
  • the metal is left in a passive state by the electropolishing process and the metal is also highly resistant to corrosion.
  • the electropolishing operation requires the use of an electrolytic fluid.
  • This fluid must dissolve the products (formed on the work piece which in this case is the metal stent surface) by electro-chemical action.
  • High current densities of 1000-5000 amps per square inch are maintained between the workpiece and a cathode.
  • a DC power supply is used to provide the required power.
  • the rate of removal is regulated by the current flow through the work piece. Corners or asperities extending from the surface of the work piece have a greater projected surface area/volume ratio than does the flat area. For this reason, material is removed from such regions at an accelerated rate.
  • a flat wire 79 may possess a rounded cornered cross sectional profile, as depicted in Figure 10.
  • the electropolishing operation may be performed as follows.
  • the electropolishing solution should be selected which meets the operational requirements.
  • An acidic solution should be selected which is compatible with the electro-chemical characteristics such that material may be removed without the production of carbides or other metal impurities on the surface which will result in corrosion.
  • a direct current (DC) power supply is provided to provide the electromotive potential required to force the electrochemical sacrifice of metal from the surface.
  • the positive (+) terminal (the anode) is attached to the workpiece, and the negative terminal is attached to a non-corrosive negative (-) terminal piece (the cathode) .
  • the stainless steel wire requires a voltage of approximately 5 volts to perform the polishing operation. This voltage is dependent on the electropolishing solution being used as the electrolyte.
  • the solution being used in the preferred embodiment is a solution of phosphoric acid, citric acid, deionized water, and ethyl alcohol. The operation is performed at an elevated temperature in order to increase the rate of metal removal and provide for the smoothest possible surface. Other electrolytes are available additionally that are effective on the stainless steel. These solutions are frequently combinations of alcohol, multiple acids, and water. Sulfuric acid based solutions are frequently used in electropolishing of stainless steel. If other metals are used in whole or in part in the braid, e.g.
  • Electropolishing solutions used on the platinum-tungsten material used on the rectangular wire used in the braid may be polished using a HF acid solution in the same manner as described above, or may be mechanically radiused prior to incorporation in the braid by winding the wire from spool to spool and passing over a sequence of polishing wheels. This may be preferred to avoid dealing with HF acid.
  • Many of the other metals which alternatively will provide opacity under X-ray also are quite noble and require HF acid for polishing. The mechanical polishing method is preferable for these metals.
  • the stainless steel that is in the austenite alloys provides a self-repairing oxide film which prevents corrosion. Passivity may be diminished or lost by any process in which a localized oxygen withdrawal occurs by any means. Heating or chemical reactions are capable of relieving this oxygen.
  • the passive state may be restored to the material by exposing the material to an oxidizing environment such as nitric acid.
  • the passivation state may be altered during the electropolishing operation if the parameters are not closely controlled.
  • the voltage driving the chemical reaction will affect the passive state of the remaining surface.
  • the voltage and temperature at which the process is operated at is 80 degrees Celsius and 5 +/- .25 volts.
  • the specific solution composition is 757.6 cc/liter phosphoric acid, 181.8 cc/liter de-ionized water, 60.6 cc/liter denatured alcohol, and 303.0 grams/liter citric acid.
  • clot formation can further be minimized by the application of one or more anti- thrombogenic coatings.
  • the braided wires are coated in two layers with a silicone oil solution. The surface is treated twice to achieve complete surface coverage. Since the engagement of the braided stent section results in a relative movement of the individual wires with respect to each other, the stent region is coated in both an expanded and contracted configuration.
  • the coating used in the preferred embodiment is Dow Corning (R) MDX4-4159 silicone fluid. The coating may be applied in accordance with the instructions in Dow Corning Bulletin 51-599 (July 1982) for the MDX4-4159 silicone fluid which is incorporated herein by reference.
  • each wire would include an oblique bend so that each wire could be connected to the actuator portion which is aligned with the axis of the hollow tube formed by the wires. Relative displacement between the ends of the wires would cause the oblique angles at the end of each wire to change thereby increasing or decreasing the diameter of the hollow tube to enable placement or removal of the stent from the vascular region of the patient's body.
  • Other alternative constructions for the stent portion may also be provided.
  • a temporary stent of a specific and selected expanded size suitable for the region of the vascular system in which it is intended to be installed Accordingly, it is presently intended with this embodiment to utilize different sizes of stents where different expanded sizes are need d.
  • a temporary stent instead of using a small size temporary stent, it is possible to utilize a large size temporary stent (i.e. one that is expandable to a large diameter) but to only expand it partially to an intermediate expanded diameter size. This could be accomplished by fixing the proximal ends of the actuator portion 18 and the inner elongate member 26 at an intermediate position between where the catheter is fully compressed and where it is fully expanded.
  • a temporary stent 80 has a stent portion 82 and a actuator portion 84.
  • the stent portion 82 is connected to the actuator portion 84 at a proximal end 86 of the stent portion 82.
  • An inner elongate member 88 extends through the stent portion 82 and the actuator portion 84.
  • the inner elongate member 88 is connected to a distal end 90 of the stent portion 82.
  • the inner elongate member 88 may be moved relative to the actuator portion 84 to cause expansion and contraction of the stent portion 82.
  • the inner elongate member 88 further includes a guidewire tip 92 that extends distally from the distal end 90 of the stent portion 82.
  • the guide wire tip 92 is flexible and formable and includes a rounded portion 94.
  • the guidewire tip 92 facilitates positioning the temporary stent 80 in the vascular system.
  • the guidewire tip 92 is depicted having a curvature although it should be understood that the guidewire would normally be provided in a straightened position and that the curvature may be imparted by a physician prior to insertion into the vascular system of the patient in order to facilitate positioning of the stent.
  • the guidewire tip 92 may assume a curvature such as depicted during its positioning in a tortuous vessel path.
  • the temporary stent 80 may be positioned by means of the guidewire tip 92 instead of over a separate guidewire that is located the inside an inner catheter (e.g. lumen 50 of inner catheter 44 in the first embodiment) .
  • a temporary stent 100 includes a stent portion 102 and a actuator portion 104 connected to each other at a proximal end 106 of the stent portion 102.
  • a distal end 108 of the stent portion 102 includes a cylindrical shaft 110 having a cylindrical opening 112 therethrough.
  • the cylindrical shaft 110 includes at least one bearing surface 116 thereupon.
  • An inner elongate number 118 is located in the hollow tube of the formed by the stent portion 102 and extends proximally as in the previous embodiments. Unlike the previous embodiments, the inner elongate member 118 is not fixed to stent portion 102.
  • the inner elongate portion 118 has a narrow distal portion 120 positioned to be slidingly received in the opening 112 of the shaft 110.
  • a first shoulder 122 on the inner elongate member 118 is located to bear upon the surface 116 when the inner elongate member 118 is moved distally.
  • the inner elongate member 118 also includes a second shoulder 126 formed distally of the narrow distal section 120.
  • the second shoulder 126 is located to bear upon another surface 128 of the inner elongate member 118. Proximal movement of the inner elongate member 118 causes the shoulder 126 to bear upon the surface 128 causing expansion of the stent portion 102.
  • the second shoulder 126 may form part of a guide wire tip 130.
  • the temporary stent should avoid or minimize clotting or platelet aggregation in and around the stent portion. Also, it is advantageous to reduce the tendency of the stent to permanently adhere to the inner surface of the vascular walls in order to facilitate removal of the stent. This may be accomplished by providing or imparting to the temporary stent properties that will minimize these tendencies.
  • the stent portion includes a coating of a slow release polymer having anti-thrombogenic properties.
  • a slow release polymer having anti-thrombogenic properties.
  • Such polymers include drugs such as urokinase, heparin, antithrombin III or other thrombon-resistive agents.
  • the polymer used may be polyethylene or a polyolefin.
  • the natural surface charge that is present intrinsically on a material is considered to be a factor in the chain of successive events that results in the formation of mural thrombus on an artificial surface.
  • the blood coagulation cascade is complex and not fully understood, it is accepted that on an artificial surface, characteristics such as low surface energy (i.e. hydrophobic) , and the electro-negativity of the surface affect the initial events that are important to subsequent reactions or events that result in the formation of thrombus.
  • the surface is coated with a silicone oil solution which is of a low surface energy.
  • Other alternative coatings that will provide relative thromboresistance include teflon, and pyrolytic carbon.
  • pyrolytic carbon has a relatively high surface energy of approximately 50 dyne/cm which is generally not considered thromboresistant, upon exposure to blood it has been observed to present a change to about 30 dyne/cm. This is considered to be thromboresistant and is thus a widely used material in coating of metal heart valves.
  • the relative success of the stent in placement in vivo is dependent upon the ability to manipulate the surface characteristics to "tune" the device to the requirements that are present but not fully understood in the blood chemistry reactions.
  • the surface of the stent portion may effectively be charged and polarized to prevent the sequence of events that results in clot formation.
  • the braid By installing an external ground plane to the patient and placing a lead to the metal surface, the braid may be energized such that it is essentially an insulated capacitor which will provide the surface charge of desired magnitude, and polarity.
  • the voltage level supplied to the wire is effectively additive to the natural negativity of the surface.
  • the net potential may be effectively adjusted to a zero, positive, or negative charge.
  • a charge is imparted to the stent portion.
  • the DC power supply 150 is located outside the vascular system. Only a small current is necessary (for example, less than 50 microamps) .
  • a lead 152 is connected to the stent portion of the temporary stent and the other lead 154 is connected to the body 156 of the patient.
  • the proximal end of the stainless steel braid comprising the stent portion could extend all the way to the proximal end of the outer catheter to form part of, or to connect to, lead 152.
  • the braid may provide a pathway proximally to the manifold which provides an electrically conductive pathway so that a surface charge may be placed which in effect overrides the natural electro-negative characteristics of the stainless steel metal surface from which the braid is formed.
  • the wires that make up the stent portion may connect to a lead at a point proximally from the proximal end of the stent portion and the lead could extend proximally.
  • the stent surface may be polarized with a time varying potential.
  • the application of a high frequency current in the kilohertz to the megahertz range is a procedure that has been tested for healing of wounds.
  • the construction of the stent portion is designed to have a periodic surface contact with the wounded vessel, and a network for applying desired voltage, and polarities and frequencies to an intimate contact with the wounded vessel.
  • the device may be constructed to apply current to the stent of 0 to 20 micro amp to the surface when an uncoated surface is used or when a noble coating such as gold or platinum is applied.
  • Gold may be applied by standard vapor deposition process known as sputter coating, or by an electro-chemical plating process. Platinum is normally electro-plated.
  • Another method for imparting a charge to the stent portion is by means of an RF signal.
  • the proximal end of the stent portion will be connected to a RF source.

Abstract

A temporary stent (10) for supporting a region of a vessel in a body comprising a stent portion (14) and an actuator portion (18) and methods for the use and manufacture thereof. The stent portion (14) is comprised of an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel and perfusable end portions (30, 34) connected to and forming ends of the vessel supporting portion and adapted to allow fluid flow therethrough. The actuator portion includes a proximal end (22) extending out of the body and a distal end (20) connected to the stent portion (14) and operable by manipulation at the proximal end (22) thereof to configure the support portion into a reduced size and an expanded size.

Description

TEMPORARY STENT AND METHODS FOR USE AND MANUFACTURE
BACKGROUND OF THE INVENTION
This invention relates to devices known as stents which provide support to a vessel, such as a blood vessel, and in particular to stents that are both temporary and removable.
Obstructive coronary artery disease is one of most serious health problems facing our society today. This disease is the result of the deposit of fatty substances on the interior surface of the walls of the arteries. The build up or lesion of such deposits results in a narrowing of the diameter of the artery which restricts the blood flow through the artery. This condition wherein the artery is narrowed is known as stenosis. The lesion may form in any part of the artery and in some instances the deposits may form at the intersection between two arteries, that is, where the section where the two arteries form a generally "Y" configuration (e.g. bifurcate, trifurcate, and so on) .
There have been significant developments of the treatment of such obstructive coronary disease in the recent past. Coronary artery bypass graft surgery is often used to treat this disease. Bypass surgery, however, has the disadvantage that it is extremely invasive and traumatic to the patient. Some of the recent developments provide a less invasive and less traumatic alternative to bypass surgery. Two of these recent developments are known as angioplasty and atherectomy procedures. Angioplasty is a procedure in which a balloon is positioned on the inside of the artery at the site of the lesion and expanded in order to compress the materials at the lesion and thus open the restricted area in the artery. In this procedure, an elastic balloon is attached to one end of a small diameter flexible catheter which includes means for inflating the balloon from the other end of the catheter. The catheter is maneuvered through the patient's vessels to the site of the lesion with the balloon in uninflated form. When the uninflated balloon is properly positioned at the lesion, the balloon is then inflated to dilatate the restricted area.
Atherectomy is a procedure in which a small cutting tool is attached to the end of a small diameter flexible catheter and maneuvered through the patient's arterial system to the site of the lesion in the diseased artery. When the cutting tool is properly positioned, the tool is used to cut and remove the deposits from the surface of the diseased artery.
Although these two procedures provide less traumatic alternatives to bypass surgery, they are not without risk. It is possible that following procedures such as angioplasty or atherectomy the artery or blood vessel may collapse or be susceptible to constriction. In some instances it may also be necessary to abort or "bail-out" procedures such as angioplasty or atherectomy due to some type of unexpected complication.
In these situations it is necessary to maintain the integrity of the region of the artery until the artery is repaired or stabilizes. That is, following some angioplasty or atherectomy procedures or in a "bail-out" situation, it may be necessary to provide support to a artery or blood vessel on a temporary basis while there is an immediate risk that the region may collapse. This support must be provided until the region is repaired or stabilized. To provide this support, a device known as a stent may be installed at the desired region. A stent is a device which is used to hold or maintain the diameter of the artery or vessel.
Although some stents are available in the art, these are generally of the type intended for permanent use. This type of permanent stent is implanted in a patient's vascular system and remains in place after the procedure or operation. Such permanent types of stents are shown, for example, in U.S. Patent Nos. 4,913,141, 4,878,906, 4,856,516 and 4,820,298. These permanent type of stents may not always be desired for the situations described above. First, it may be unnecessary and even undesirable to install a permanent device when only temporary support is needed. Further, these permanent type of stents may require a relatively complicated procedure to install. Further, use of permanent stents results in extended hospital observation and recovery time. Additionally, a complement of drug therapies are required in order to offset the bioreaction resulting in thrombus formation or smooth muscle cell proliferation on the stent surface. These drug therapies may be required for a significant period of time until new normal endothelial cells have formed. In situations such as a "bail-out it is desirable for the physician to have the ability to quickly maneuver the stent to the desired location and quickly and easily place the stent in its operating mode.
A temporary stent on the other hand may be particularly useful in situations where it is intended to be used in the patient only for several minutes or days and then removed. For example, use of a temporary stent in a bail-out situation will enable the physician to defer a more complicated procedure until a patient's condition is more stable, or in some cases eliminate further procedures by resecuring the vessel geometry which allows near normal blood flow.
It is essential that a temporary stent be relatively easy to both install and remove. Since the temporary stent remains in place for a period of time, it is important that the temporary stent not block the flow of blood through the vessel. That is, the blood must be able to travel through the vessel in which the temporary stent is installed while the stent is in place. Further, since the lesions often occur at the intersection of two vessels, in order to position the temporary stent it is may be necessary to place the stent across the intersection. Therefore, it is critical that the stent provide a flow path radially as well as axially or longitudinally. This arrangement will allow blood flow to both of the intersecting arteries.
It is also desirable to have the ability to deliver medicines to the vessel either upstream or downstream of temporary stent while the stent is in place.
Since the temporary stent will be removed after a period of time, it is important that the temporary stent not permanently adhere to the inner walls of the vessel in which it is placed. In addition, a temporary stent should have no tendency, or only a minimal tendency, to cause clotting.
Accordingly, it is an object of the present invention to provide a stent that may be placed temporarily in a patient's vascular system and which is readily removable. SUMMARY OF THE INVENTION
The present invention relates to a temporary stent for supporting a region of a vessel in a body comprising a stent portion and an actuator portion and methods for the use and manufacture thereof. The stent portion is comprised of an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel. The stent portion also includes perfusable end portions connected to and forming ends of the vessel supporting portion and adapted to allow fluid flow therethrough. The actuator portion includes a proximal end extending out of the body and a distal end connected to the stent portion and operable by manipulation at the proximal end thereof to configure the support portion into a reduced size and an expanded size.
With this arrangement, the temporary stent may be positioned in the desired region in its contracted form and then expanded to provide the desired support to the vessel. The temporary stent may be left in place for a selected period of time and then be easily removed by the physician. Significantly, the arrangement of the present invention allows the stent to remain in place without significantly interfering with the flow of fluids through the vessel.
In one preferred arrangement, the stent is attached to the distal end of a flexible catheter and a fluid conduit is provided which extends from the proximal end of the catheter to a point close to the stent. This fluid conduit provides a channel through which medicine may be introduced to an area near to the stent. Angiographic fluids, such as dyes, injected into the blood flow in the vessel allow imaging of the vessel and blood as it passes through the stent.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts a first preferred embodiment of the present invention.
Figure 2 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in a reduced contracted configuration.
Figure 3 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in an expanded configuration.
Figure 4 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 5 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 6 depicts a distal portion of another embodiment of the present invention.
Figure 7 depicts a distal portion of another embodiment of the present invention in a contracted configuration.
Figure 8 depicts the distal portion of the embodiment shown in Figure 7 in an expanded configuration.
Figure 9 depicts another embodiment of the present invention.
Figure 10 is a cross section of an embodiment of a wire component along lines 10-10' of Figure 2.
DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
Referring to Figure l, there is depicted a first embodiment of the present invention. The embodiment of Figure l is a temporary stent 10 which can be placed in the vascular system of a patient after a procedure such as angioplasty, atherectomy or other interventional therapies. Although the temporary stent 10 is particularly useful in procedures involving blood vessels, it may be used in other fluid carrying vessels in the patient's body. As used herein, the term "vascular system" refers to a vessel for conveying body fluids. The temporary stent 10 is intended for placement in a vascular system for limited durations of time from several minutes to up to several days.
In the embodiment of the invention depicted in Figure 1, the temporary stent 10 includes a perfusable stent portion 14 and an actuator portion 18. The stent portion 14 is connected to a distal end 20 of the actuator portion 18. When the temporary stent 10 is being used in a patient, the actuator portion 18 extends proxi ally from its connection to the stent portion 14 through the vascular system and out of the body of the patient. The proximal end 22 of the actuator portion 18 which extends out the body of the patient is connected to one or more and preferably two manifolds 24 and 26.
The stent portion 14 is expandable and contractable so that it can be positioned in the vascular system at the specific location where needed and then expanded to an appropriate size (i.e. approximately the same diameter as the vessel in the region where placed) thus supporting that vascular region. When in its expanded configuration, the stent portion 14 provides support to the vascular walls thereby preventing constriction of the vascular region in which it is located and maintaining the vascular lumen open.
The construction and materials for the stent portion 14 should provide that the stent be perfusable. i.e. it should allow blood flow therethrough both in the axial direction of the vessel to maintain blood flow through the region in which the stent is located as well as in the radial direction so that any vessels that branch off from the region of the vessel into which the stent portion is placed will not be occluded. Thus, the stent portion 14 should be relatively transparent to blood flow in order to maintain vascular function while at the same time providing support for the vessel walls in the region where it is located.
Expansion and contraction of the stent portion 14 inside the patient's body may be accomplished from outside of the patient's body by means of manipulation of the actuator portion 18 from the proximal end 22 thereof which is located outside the patient's body. In this embodiment, the actuator portion 18 comprises a first elongate member 28 that connects to a proximal end 30 of the stent portion 14 and a second elongate member 32 that connects to the distal end 34 of the stent portion 14. Relative movement of the first elongate member 28 and the second elongate member 32 causes expansion and contraction of the stent portion 14, as explained in more detail below. The distal end 20 of the actuator portion 18 remains in place in the body during the period of time that the stent portion 14 is in place in the vascular system and during this time the proximal end 22 of the actuator portion 18 extends out of the patient's body. At the proximal end of the actuator portion 18, the first elongate member 28 terminates at a manifold 24 and the second elongate member 32 terminates at the manifold 26. In a preferred embodiment, these manifolds include hemostatic valves and Y-connecters for administering fluids, such as medicines through these manifolds, as described below. In a preferred embodiment, the stent portion 14 is comprised of a braid made of a plurality of helically wound wires forming an elongated hollow tube. Typically, half of the wires forming this tube will be wound in one helical direction and the other half will be wound in the opposite helical direction and interwoven with the first half. Braiding of these wires provides for an elongated, expandable hollow tube that can, in a preferred embodiment, increase in diameter when the ends of the hollow tube are moved closer relative to each other and decrease in diameter when the ends of the hollow tube are move apart relative to each other. The ratio by which the stent portion expands depends upon the spacing between adjacent wires that make up the braid as well as the cross sectional dimensions of each of the individual wires.
The stent portion 14 may be provided in a wide range of sizes and stiffnesses to meet the requirements for use with different lesions or flaps in a patient's vascular system. The stent portion 14 is constructed to be flexible enough to traverse its way to the region of the vascular system where it is to be located and expanded to provide support for the region of the vascular system, such as the site of previous angioplasty or other treatment.
The stent portion 14 terminates in a distal end 34. Located inside the hollow tube of the stent portion 14 is the second (or inner) elongate member 32. The second elongate member 32 is connected to the distal end 34 of the stent portion 14, as explained below. The second elongate member 32 extends proximally from its connection to the distal end 34 of the stent portion 14, through the hollow tube of the stent portion 14, and through an inner lumen of the first elongate member 28 to the proximal end thereof. In accordance with this embodiment, relative movement between the first elongate member 28 and the second elongate member 32 causes corresponding movement of the proximal end 30 and distal end 34 of the stent portion 14 thus in turn causing expansion or contraction of the diameter of the elongate hollow tube of the stent portion 14.
In Figure 2, the temporary stent 10 is depicted in its constricted configuration with the elongate hollow tube of the stent portion 14 having a reduced diameter. In this configuration, the second elongate member 32 extends distally from the first elongate member 28 so that the length of the stent portion 14 is LI. In Figure 3, the second elongate member 32 is positioned at a location more proximate relative to the first elongate member 28 than in Figure 2 (i.e., in the direction of arrow 35) causing the length of the stent portion 14 to be equal to L2 (L2 being less than LI) . In the process of moving proximally relative to the first elongate member 28, the second elongate member 32 causes the proximal and distal ends 30 and 34, respectively, of the stent portion 14 to move relatively closer together thus causing the diameter of the elongate hollow tube of the stent portion 14 to expand to a dimension suitable for supporting a region of the vascular system. The temporary stent 10 can be maintained in this expanded configuration by fixing the proximal ends of the first and second elongate members 28 and 32 for the duration of the time that the temporary stent 10 is maintained in the vascular system. This may be done by attaching a clamp 39 or similar device to the proximal ends of the first elongate member 28 and the second elongate member 32 at the manifolds 24 and 26. These two elongate members can be later disengaged from each other to permit reducing the diameter of the temporary stent 10 for removal thereof from the body.
In order to provide a means by which the position of the temporary stent 10 in the body of the patient can be determined, one or more radiopaque markers, e.g. 40 and 41 may be located on a distal region of the stent, for example on a distal region of the second elongate member 32. These markers may be bands of radiopaque materials such as platinum, tantalum, gold, tungsten or a tungsten-iridium alloy.
Referring to Figure 4, there is depicted a longitudinal cross section of the distal end of the second elongate member 32. In this embodiment, the second elongate member 32 is an inner catheter 44. As depicted in Figure 2, the distal end 34 of the stent portion 14 surrounds an outside wall of the inner catheter 44. A collar 46 surrounds and affixes the distal ends of the wires that make up the braid of the stent portion 14 to the distal end of the inner catheter 44 (i.e. first elongate member 32). The collar 46 may be made of a balloon tubing polyolefin or other ultra-thin wall polymers. The collar 46 may be heated to fuse to the outer wall of the inner catheter 44 or connected thereto by an adhesive or other suitable means. In this manner, the distal end 34 of the stent portion 14 may be securely fixed to the inner catheter 44 suitably for the duration of the use of the temporary stent 10. A distal tip 48 of the temporary stent 10 is formed of an extension of the inner catheter 44 distally past the collar 46. This extension may be approximately 0.25 cm. The inner catheter 44 has a lumen 50 therewithin that communicates with an opening 52 at the distal tip 48. Referring to Figure 5, there is a longitudinal sectional view depicting a portion of the proximal end 30 of the stent portion 14 and the actuator portion 18 and specifically the connection of the proximal end 30 of the stent portion 14 to the first elongate member 28 of the actuator portion 18. In this embodiment, the first elongate member 28 is an outer catheter 54. As shown in Figure 5, the outer catheter 54 includes an inner tubular layer 56 and an outer tubular layer 58 that is concentric with the inner tubular layer 56. The outer diameter of the outer catheter 54 would be approximately close to, but may be slightly larger than, the contracted diameter of the stent portion 14. Thus, for coronary applications, the outer catheter 54 may be approximately 1.35 mm, and for peripheral applications the outer catheter 54 may have a diameter of approximately 2.10 mm. The length of the outer catheter 54 could be made to various sizes to be suitable for different treatment sites. For coronary applications, the length of the outer catheter 54 would be approximately 175 cm, for example.
In this embodiment, the proximal end 30 of the stent portion 14 is secured between the inner and outer concentric tubular layers 56 and 58 by extending the wires of the braid proximally between these concentric layers. The concentric tubular layers 56 and 58 and the wires of the braid of the stent portion 14 may be bonded together by an appropriate adhesive or by heating. A frictional fit may also be suitable. Preferably, the wires of the braid extend the entire length proximally to the proximal end of the first elongate member 28. Alternatively, the wires of the braid of the stent portion 14 may extend only a short distance or an intermediate distance proximally between the concentric tubular layers 56 and 58. In the preferred embodiment, the inner tubular layer 56 terminates a distance proximally from the distal end of the outer tubular layer 58. This enables the outer catheter 54 (i.e., first elongate member 18) to be reduced in diameter in the distal region thereof forming a necked down portion 60 to facilitate positioning the temporary stent 10 in a region of the vascular system. The necked down portion 60 of the outer catheter 54 may be approximately 3 to 30 cm in length.
Referring again to Figure 3, when the stent portion is in its expanded configuration, the proximal 30 and distal 34 ends of the stent portion 14 will assume a proximal and distal truncated conical profile regions 62 and 64. These truncated conical profile regions 62 and 64 taper from a narrow dimension where the wire braid is affixed to the actuator portion 18 proximally and distally (i.e., first and second elongate members 28 and 32) up to the expanded diameter of the stent portion 14. These regions 62 and 64 may be linearly tapered, but a non-linear taper may also be provided. The type of taper depends upon the type of braiding method used. Because the diameter of the second elongate member 32 is less than the diameter of the first elongate member 18, the distal tapered region 64 may not correspond exactly in size or slope to the proximal tapered region 62. In both the proximal tapered region 62 and the distal tapered region 64, the braiding method used preferably provides for relatively large distances between adjacent wires to provide correspondingly large openings around and through the plurality of wires at the ends of the stent portion 14 to facilitate blood flow therethrough.
In this embodiment, the temporary stent 10 may be positioned in the vascular region over a guidewire 70 through the lumen 50 of the inner catheter 44. The guidewire 70 may be a standard guidewire suitable for the region of the vascular system into which the stent will be located. According to this embodiment, the guidewire 70 is positioned in the vascular system across the region where it is desired to install the temporary stent 10. The guidewire 70 may be positioned by standard procedures. The diameter of the lumen 50 of the inner catheter 44 is of a sufficient size to allow the stent portion 14 to be advanced in the vascular system over the guidewire 70. The temporary stent 10 including the stent portion 14 and the distal end of the actuator portion 18 is advanced over the guidewire 70. The lumen 50 of the inner catheter may be compatible with 0.014, 0.016, or 0.018 guidewires for coronary applications and with up to 0.038 guidewires for peripheral applications.
Alternatively, the temporary stent 10 could be located in the vascular region by guiding it through a separate catheter (e.g. a delivery catheter) large enough to contain the temporary stent 10 in its contracted configuration.
For coronary applications, the stent portion 14 of this embodiment is expandable from a size of approximately 1.25 mm or less to up to approximately 4.0 mm. When used for peripheral applications, the stent portion 14 of the temporary stent 10 may have a contracted diameter of less than approximately 2.0 mm and an expanded diameter of up to approximately 6.0 mm. The length of the stent portion 14 is approximately 2.5 to 5 cm when in its most extended position (i.e. when the diameter of the stent portion 14 is in its contracted configuration) . When the diameter of the stent portion is in its expanded configuration, the length of the stent portion is somewhat less, e.g. approximately 1.5 to 3.5 cm.
In this embodiment, fluids such as medicines may be introduced to the vascular system via the lumen 50 of the inner catheter 44 as well as through a lumen 72 of the outer catheter 54 around the inner catheter 44. Medicines introduced via the inner catheter 44 will enter the vascular system at the distal end 48 of the stent portion 14 via opening 52. In this embodiment, sufficient space is provided in the lumen 72 of the outer catheter 54 around the inner catheter 44, so that a second passageway for the introduction of fluids such as medicines to the vascular system is also provided. Medicines introduced via the lumen 72 of the outer catheter 54 will enter the vascular system at the proximal end 30 of the stent portion 14. In this manner, the attending physician has the choice of selecting the point of entry for medicines administered e.g., either upstream or downstream of the stent portion 14. For instance, medicines, such as non- thrombogenic drugs, can be administered upstream of the stent portion 14 where they would be most effective in the region of the stent portion 14.
To remove the temporary stent 10, the stent portion 14 is first contracted from its expanded configuration to a reduced configuration. To do this, the first elongate member 28 is moved proximally relative to the second elongate member 32 thereby drawing down the diameter of the stent portion 14 to a size to facilitate removal from the vascular system. The wires of the stent portion 14 should smoothly peel from the vessel wall causing no or only minimal trauma. It is not necessary that the stent portion 14 be drawn down entirely to its completely reduced size. It is sufficient that the stent portion 14 is drawn down sufficiently to disengage the inner walls of the vascular region and to be of a size sufficiently small to traverse the vascular system out of the body. Then, after the stent portion 14 is in a reduced configuration it may be removed from the vascular system by drawing it out by means of the attached actuator portion 18.
In the first presently preferred embodiment of the present invention, the inner catheter 44 is comprised of a .021 X .028 inch polymeric tubing. The tubing used may be a blended Poly-Ethylene comprised of High Density Polyethylene (HDPE) and Low Density Poly- Ethylene (LDPE) . Alternatively, the inner catheter 44 may also be constructed of Poly-Propylene, TPFE teflon or TPX. (TPX is a trade name for the Methyl Methylpentene Copolymer manufactured by Mitsui Plastics, Inc. and distributed from White Plains, NY). The use of TPX enables the stent to be used for ultrasound imaging of the vessel that is being supported by the stent because the acoustical properties of this polymer match to that of water and blood.
Referring to the first elongate member 28, the inner tubular layer 56 may be constructed of the same combination of polymers described for the inner catheter 44. The inner tubular layer 56 may terminates 3 to 30 cm proximally from the proximal end 30 of the stent portion 14. This provides for the ability to reduce the section of the outer layer 58 by way of a drawing (or necking operation) on the outer layer 58. The preferred size for this inner tubular layer 56 of the first elongate member 28 is .033 X .039 inch. The outer tubular layer 58 of the first elongate member 28 may also be constructed of blended HDPE-LDPE, or polypropylene. The dimensions of the outer tubular layer 58 of the preferred embodiment may be .045 X .053 inches in the proximal section of the first elongate member 28 extending from the manifold 24 at the proximal end to approximately 3 to 30 cm from the proximal portion 30 of the stent portion 14. From this point distally, the outer tubular layer 58 may be preferable reduced to .039 X .045. This may be accomplished by a necking or drawing operation which is achieved by pulling the tube through a heated die and allowing the plastic to reflow.
The inner dimension of the outer tubular layer 58 as well as the distal necked region 60 is adjusted accordingly for a 3.0 or 3.5 mm stent as may be seen to accommodate the wire of greater thickness. Since the outer diameter of the inner tubular layer 58 is .039 inches the placement of the braid on top of this layer, i.e. in the lumen 72, adds a factor of four times the wire thickness to the profile of the device prior to installation of the outer tubular layer 58. It is therefore apparent that the inner diameter of the outer tubular layer 58 should be adjusted to a minimum of .047 inches for the 3.0 mm and 3.5 mm versions. The tubing dimension may then be adjusted for the outer tubular layer to .055.
When devices are designed for use within the coronary arterial system size becomes a very significant factor. Each 1/1000th of an inch is significant both because of the primary concern which is restriction of flow, but also because of the added stiffness that results when a composite of tubular layers are sandwiched together to form the actuator member. For this reason, in the preferred embodiment, wire of rectangular cross section (herein referred to as flat wire) are utilized. The preferable size wire to make a 2.0 mm stent is .003 inches. For a 2.5 mm stent, wire of a size of .003 to .0035 may be used. For a 3.0 and 3.5 mm stent, wire of either .0035 or .0040 should be used. From this, the advantage of using flat wire becomes apparent. For each of the stent sizes, added thickness due to the braid is detailed below.
Figure imgf000020_0001
From the above, the significance of the use of flat wire can be appreciated. It may be seen that a large profile change results using flat wire as opposed to round wire. Additionally, the use of the larger flat wire results in devices that are considerably stiffer.
In the preferred embodiment, the braiding operation uses flat wire. In the preferred embodiment, a 2.0 mm stent is constructed with a braid mesh network using stainless steel wire of rectangular cross section with a thickness of .001 inch X .004 inch. In the preferred embodiment, for a 2.5 mm stent the wire used is stainless steel wire with a rectangular cross section of .0015 inches in thickness and .004 inch in width. In the preferred embodiment, the 3 mm stent is constructed with a stainless steel wire of rectangular cross section with .002 inch thickness and .004 inch width. A 3.5 mm stent is constructed with either a .002 inch thickness and.004 inch width, or a .002 inch thickness and .005 inch to .007 inch width.
The wires that are used for the braid of the stent portion can be fragile due to their small size and care should be exercised in the manufacturing process. This is particularly true for the smaller wires such as the .003 inch round or the .0008 to .0015 thickness flat wires.
In the preferred embodiment, the wire used in each of the aforementioned braiding operations is 304 stainless steel in a spring temper. The specific wire used is the Hyten (TM) wire available from Fort Wayne Metals of Fort Wayne, Indiana. Additionally, any one or more or and preferably 2, 3, or 4 of the 8 wires that comprise the braid may be made of an alloy of 92% platinum and 8% tungsten for the purpose of providing radiopacity. These alloys may are commercially available from a number of sources, such as Sigmund Cohn Corp. of Mount Vernon, N.Y., or California Fine Wire of Grover City, California.
The braiding process of the present invention requires modification of a commercially available braiding machine to achieve the desired consistency and braid density. In the preferred embodiment, for both the round and the flat wires, the braid pattern is composed of 8 wires. Braiding machines range in size from 16 carriers to 100 carriers. The braiding machine used for the manufacture of the stent described herein is a modified KoKobun SL-4-16 braider available from Wardwell Braiding Machine Co. of Rhode Island, NY. This same company also manufacturers a series of braiders under the New England Butt trade name. The braiders may be manufactured to accommodate 4, 6, 8, 10, 12, 16, or 24 bobbins in the machine groups defined as NE Butt #1, #2, or the B-ll-8. These are all very small bench top versions that are used for small fibers or wire when fragile tensioning is required. The KoKobun is similar to the New England #2. The N E Butt B-9 which is a New England Butt #1 could conceivably be modified to make a 6 or a 5 wire braid which would may also be used for this application.
Machine modifications include the removal of 8 of the 16 carriages, as well as the installation of ultra light tensioning springs on the braider carriages. Additionally the tent angle (i.e. the angle with which the wires approach the central core on which the braid is being installed) normally is free to float up and down as the braiding wire position and rate equilibrate on the central core. For the application of flat wire, the wire may tend to get caught on other wires which are being applied in the opposing direction. The wires then would get flipped over every few linear inches of braid therefore making the segment unusable or incorporatable within the catheter. This problem may be eliminated by providing an angled guide made of a low friction material such as teflon and containing the angle for which the desired tent angle should be guided.
The size and density of the stent is controlled by three variables: the size of the central core to which the braid is being applied; the rate of advancement of the central core through the braid region; and the angular velocity of the braiding carriages. These variables relative to each other determine the "pick" (number of wire group intersections per inch) density of the braid pattern. These variables also determine the size of the stent that will be manufactured. In the preferred embodiment, a 2.0 mm stent is made on a central core with a size of .050 inches and a density of 10 per inch. When removed from the core the stent will spring from the I.D. of .055 to 2.0 mm and have a pick density of approximately of 7 to 15 per inch or approximately .14 to .07 inches between groups or 3.6 mm to 1.8 mm. The degree for which the stent expands when removed from the core depends on the pick density during the braiding operation.
The table below outlines the preferred expanded pick densities for the individual stent configurations. The braiding machine used must be modified so that the take up velocity of the central core and the radial velocity may be adjusted very precisely to achieve the exact density required. Due to the addition of the guide, as explained above, the density of the braid will not be allowed to assume its own pattern density by climbing up and down the central core, but instead will assume the required density. pic distance when expanded 1.8 to 3.6 mm 1.8 to 3.6 mm 1.8 to 3.6 mm
Figure imgf000023_0001
1.8 to 3.6 mm
From the table, the desired density in this preferred embodiment is obtained by placing the bridges 1.8 to 3.6 mm apart. As mentioned above and unlike a dilation device, an feature of the temporary stent is that it is highly perfusable. This is accomplished in part by minimizing the density of metal within the vessel which may restrict the blood flow both though the ends of the stent and also radially from the sides of the stent. This is important because frequently side branches to the blood vessel are contained in the stent region and flow must exit the stent to keep these side branches perfused. The area or size of the stent should be minimized to maximize perfusion while maintaining sufficient structural support for a flap or other damaged part of the vessel.
The stent portion should not only be perfusable to allow blood flow therethrough, but should also minimize surfaces upon which a thrombus might form. The vascular system is very active with respect to clot formation once a vessel has been damaged or subjected to other trauma such as during an angioplasty. Any device that is installed for more than a few minutes is susceptible to clot formation. Because in some embodiments, the temporary stent may be used for up to several days, it should also provide for minimization of clot formation.
One way the temporary stent minimizes clot formation is by preparation of the surfaces of the wires of the stent portion. The wires of the braid in the preferred embodiment are made of rectangular wires braided into a 4, or 8 wire braid and rectangular wire may, by reason of the manufacturing processes, have edges that are very and/or sharp. The wire is made by initially drawing it through a die in order to form the specific size that is desired. During this process the temper of the spring may be modified by the cold work that is being induced into the wire from the forceful shaping of the wire. In the case of the HyTen 304 SS wire, the spring tempers are being achieved with pressures which are substantially greater than 300,000 psi. This spring temper is very desirable from the standpoint of imparting desirable properties to the stent. Specifically, the stent must be resilient to return from its initial contracted configuration to the full expanded state with only a minimal application of external force. The temper is relevant to the fabrication process and ultimately to the product performance.
The edges formed on the flat wire are rounded off. The preferred method used to radius the corners of the flat wire is electropolishing which removes edges or protrusions of the material and passivates the metal without altering the bulk properties of the metal. The metal is left in a passive state by the electropolishing process and the metal is also highly resistant to corrosion.
The electropolishing operation requires the use of an electrolytic fluid. This fluid must dissolve the products (formed on the work piece which in this case is the metal stent surface) by electro-chemical action. High current densities of 1000-5000 amps per square inch are maintained between the workpiece and a cathode. A DC power supply is used to provide the required power. The rate of removal is regulated by the current flow through the work piece. Corners or asperities extending from the surface of the work piece have a greater projected surface area/volume ratio than does the flat area. For this reason, material is removed from such regions at an accelerated rate. Further, this operation is ideal for smoothing the flat wire in the stent region and radiusing the corners which other wire would exhibit sufficient sharpness to potentially scrape the endothelial cells from the inside of the vessel thus promoting thrombus. After electropolishing, a flat wire 79 may possess a rounded cornered cross sectional profile, as depicted in Figure 10.
The electropolishing operation may be performed as follows. The electropolishing solution should be selected which meets the operational requirements. An acidic solution should be selected which is compatible with the electro-chemical characteristics such that material may be removed without the production of carbides or other metal impurities on the surface which will result in corrosion. A direct current (DC) power supply is provided to provide the electromotive potential required to force the electrochemical sacrifice of metal from the surface. The positive (+) terminal (the anode) is attached to the workpiece, and the negative terminal is attached to a non-corrosive negative (-) terminal piece (the cathode) .
The stainless steel wire requires a voltage of approximately 5 volts to perform the polishing operation. This voltage is dependent on the electropolishing solution being used as the electrolyte. The solution being used in the preferred embodiment is a solution of phosphoric acid, citric acid, deionized water, and ethyl alcohol. The operation is performed at an elevated temperature in order to increase the rate of metal removal and provide for the smoothest possible surface. Other electrolytes are available additionally that are effective on the stainless steel. These solutions are frequently combinations of alcohol, multiple acids, and water. Sulfuric acid based solutions are frequently used in electropolishing of stainless steel. If other metals are used in whole or in part in the braid, e.g. platinum or tungsten, in order to provide for radiopacity, modifications to the method may be appropriate. Electropolishing solutions used on the platinum-tungsten material used on the rectangular wire used in the braid may be polished using a HF acid solution in the same manner as described above, or may be mechanically radiused prior to incorporation in the braid by winding the wire from spool to spool and passing over a sequence of polishing wheels. This may be preferred to avoid dealing with HF acid. Many of the other metals which alternatively will provide opacity under X-ray also are quite noble and require HF acid for polishing. The mechanical polishing method is preferable for these metals.
The ease of electropolishing the stainless steel and the smooth-burr free surface that is provided makes this the preferred method over mechanical removal. It must be understood that mechanical removal is also possible and relatively easy with the stainless steel.
The stainless steel that is in the austenite alloys provides a self-repairing oxide film which prevents corrosion. Passivity may be diminished or lost by any process in which a localized oxygen withdrawal occurs by any means. Heating or chemical reactions are capable of relieving this oxygen. The passive state may be restored to the material by exposing the material to an oxidizing environment such as nitric acid. The passivation state may be altered during the electropolishing operation if the parameters are not closely controlled. The voltage driving the chemical reaction will affect the passive state of the remaining surface. In the case of the preferred process utilizing the phosphoric acid solution the voltage and temperature at which the process is operated at is 80 degrees Celsius and 5 +/- .25 volts. The specific solution composition is 757.6 cc/liter phosphoric acid, 181.8 cc/liter de-ionized water, 60.6 cc/liter denatured alcohol, and 303.0 grams/liter citric acid.
In addition to the electropolishing step described above, clot formation can further be minimized by the application of one or more anti- thrombogenic coatings. In the preferred embodiment, the braided wires are coated in two layers with a silicone oil solution. The surface is treated twice to achieve complete surface coverage. Since the engagement of the braided stent section results in a relative movement of the individual wires with respect to each other, the stent region is coated in both an expanded and contracted configuration. The coating used in the preferred embodiment is Dow Corning (R) MDX4-4159 silicone fluid. The coating may be applied in accordance with the instructions in Dow Corning Bulletin 51-599 (July 1982) for the MDX4-4159 silicone fluid which is incorporated herein by reference.
Although a braid is a presently preferred construction for the perfusable stent portion 14, other alternative embodiments may include a plurality of parallel wires forming a hollow cylindrical tube each wire substantially parallel to the axis of the hollow cylindrical tube. In this alternative construction, at the ends of the elongate hollow tube formed by the plurality of wires, each wire would include an oblique bend so that each wire could be connected to the actuator portion which is aligned with the axis of the hollow tube formed by the wires. Relative displacement between the ends of the wires would cause the oblique angles at the end of each wire to change thereby increasing or decreasing the diameter of the hollow tube to enable placement or removal of the stent from the vascular region of the patient's body. Other alternative constructions for the stent portion may also be provided.
In accordance with the present embodiment, it is presently preferred to utilize a temporary stent of a specific and selected expanded size suitable for the region of the vascular system in which it is intended to be installed. Accordingly, it is presently intended with this embodiment to utilize different sizes of stents where different expanded sizes are need d. Alternatively, where there is a need to app.L/ a temporary stent in a small size vessel, instead of using a small size temporary stent, it is possible to utilize a large size temporary stent (i.e. one that is expandable to a large diameter) but to only expand it partially to an intermediate expanded diameter size. This could be accomplished by fixing the proximal ends of the actuator portion 18 and the inner elongate member 26 at an intermediate position between where the catheter is fully compressed and where it is fully expanded.
These dimensions provided above are intended as approximate and other sizes and dimensions may be selected and designed in accordance with the teachings of the present invention.
Referring to Figure 6, there is depicted the distal end of another embodiment of the present invention. The proximal end (not shown) could function similarly as in the first described embodiment. In this embodiment, a temporary stent 80 has a stent portion 82 and a actuator portion 84. The stent portion 82 is connected to the actuator portion 84 at a proximal end 86 of the stent portion 82. An inner elongate member 88 extends through the stent portion 82 and the actuator portion 84. As in the previous embodiment the inner elongate member 88 is connected to a distal end 90 of the stent portion 82. Also, as in the previous embodiment, the inner elongate member 88 may be moved relative to the actuator portion 84 to cause expansion and contraction of the stent portion 82.
In this embodiment, the inner elongate member 88 further includes a guidewire tip 92 that extends distally from the distal end 90 of the stent portion 82. The guide wire tip 92 is flexible and formable and includes a rounded portion 94. The guidewire tip 92 facilitates positioning the temporary stent 80 in the vascular system. In Figure 4, the guidewire tip 92 is depicted having a curvature although it should be understood that the guidewire would normally be provided in a straightened position and that the curvature may be imparted by a physician prior to insertion into the vascular system of the patient in order to facilitate positioning of the stent. The guidewire tip 92 may assume a curvature such as depicted during its positioning in a tortuous vessel path. In this embodiment, the temporary stent 80 may be positioned by means of the guidewire tip 92 instead of over a separate guidewire that is located the inside an inner catheter (e.g. lumen 50 of inner catheter 44 in the first embodiment) .
Referring to Figures 7 and 8, there is depicted another embodiment of the present invention. In Figures 7 and 8, a temporary stent 100 includes a stent portion 102 and a actuator portion 104 connected to each other at a proximal end 106 of the stent portion 102. In this embodiment, a distal end 108 of the stent portion 102 includes a cylindrical shaft 110 having a cylindrical opening 112 therethrough. The cylindrical shaft 110 includes at least one bearing surface 116 thereupon. An inner elongate number 118 is located in the hollow tube of the formed by the stent portion 102 and extends proximally as in the previous embodiments. Unlike the previous embodiments, the inner elongate member 118 is not fixed to stent portion 102. Instead, the inner elongate portion 118 has a narrow distal portion 120 positioned to be slidingly received in the opening 112 of the shaft 110. A first shoulder 122 on the inner elongate member 118 is located to bear upon the surface 116 when the inner elongate member 118 is moved distally. The inner elongate member 118 also includes a second shoulder 126 formed distally of the narrow distal section 120. The second shoulder 126 is located to bear upon another surface 128 of the inner elongate member 118. Proximal movement of the inner elongate member 118 causes the shoulder 126 to bear upon the surface 128 causing expansion of the stent portion 102. As shown in Figure 8, the second shoulder 126 may form part of a guide wire tip 130. However, other configurations for the tip are also suitable. With the embodiment of the invention depicted in Figures 7 and 8, limited axial movement of the inner elongate member 118 is provided which may be suitable and desirable for positioning and removal of the removable stent. s shown in Figures 7 and 8, the surfaces 116 and 128 and the shoulders 122 and 126 may be formed to prevent removal of the inner elongate member 118 from the actuator portion 104 and stent portion 102 although removability may be provided by alignment of the shoulders 106 with the bearing surface 128. As in the previously described embodiment, with this embodiment a separate guide wire is not required to position the temporary stent inside the vascular system.
As described above, because the temporary stent will be left in the vascular system for a period of time, the temporary stent should avoid or minimize clotting or platelet aggregation in and around the stent portion. Also, it is advantageous to reduce the tendency of the stent to permanently adhere to the inner surface of the vascular walls in order to facilitate removal of the stent. This may be accomplished by providing or imparting to the temporary stent properties that will minimize these tendencies.
In one alternative embodiment, the stent portion includes a coating of a slow release polymer having anti-thrombogenic properties. Such polymers include drugs such as urokinase, heparin, antithrombin III or other thrombon-resistive agents. The polymer used may be polyethylene or a polyolefin.
The natural surface charge that is present intrinsically on a material is considered to be a factor in the chain of successive events that results in the formation of mural thrombus on an artificial surface. Although, the blood coagulation cascade is complex and not fully understood, it is accepted that on an artificial surface, characteristics such as low surface energy (i.e. hydrophobic) , and the electro-negativity of the surface affect the initial events that are important to subsequent reactions or events that result in the formation of thrombus. For this reason, in the preferred embodiment, the surface is coated with a silicone oil solution which is of a low surface energy. Other alternative coatings that will provide relative thromboresistance include teflon, and pyrolytic carbon. While pyrolytic carbon has a relatively high surface energy of approximately 50 dyne/cm which is generally not considered thromboresistant, upon exposure to blood it has been observed to present a change to about 30 dyne/cm. This is considered to be thromboresistant and is thus a widely used material in coating of metal heart valves. The relative success of the stent in placement in vivo is dependent upon the ability to manipulate the surface characteristics to "tune" the device to the requirements that are present but not fully understood in the blood chemistry reactions.
Other methods may be used to provide this property. For example, the surface of the stent portion may effectively be charged and polarized to prevent the sequence of events that results in clot formation. By installing an external ground plane to the patient and placing a lead to the metal surface, the braid may be energized such that it is essentially an insulated capacitor which will provide the surface charge of desired magnitude, and polarity. The voltage level supplied to the wire is effectively additive to the natural negativity of the surface. The net potential may be effectively adjusted to a zero, positive, or negative charge. Referring to Figure 9, a charge is imparted to the stent portion. The DC power supply 150 is located outside the vascular system. Only a small current is necessary (for example, less than 50 microamps) . This could be provided by a small battery such as a watch battery. This would be sufficient to impart a charge to the stent portion to minimize the tendency for clotting materials to form on the stent portion. The polarity may be selected based upon consider¬ ation of factors, such as material, coating, medication, etc. A lead 152 is connected to the stent portion of the temporary stent and the other lead 154 is connected to the body 156 of the patient. As described above, the proximal end of the stainless steel braid comprising the stent portion could extend all the way to the proximal end of the outer catheter to form part of, or to connect to, lead 152. The braid may provide a pathway proximally to the manifold which provides an electrically conductive pathway so that a surface charge may be placed which in effect overrides the natural electro-negative characteristics of the stainless steel metal surface from which the braid is formed. Alternatively, the wires that make up the stent portion may connect to a lead at a point proximally from the proximal end of the stent portion and the lead could extend proximally.
Additionally by providing a waveform polarizing function, the stent surface may be polarized with a time varying potential. The application of a high frequency current in the kilohertz to the megahertz range is a procedure that has been tested for healing of wounds. The construction of the stent portion is designed to have a periodic surface contact with the wounded vessel, and a network for applying desired voltage, and polarities and frequencies to an intimate contact with the wounded vessel. The device may be constructed to apply current to the stent of 0 to 20 micro amp to the surface when an uncoated surface is used or when a noble coating such as gold or platinum is applied. Gold may be applied by standard vapor deposition process known as sputter coating, or by an electro-chemical plating process. Platinum is normally electro-plated.
Another method for imparting a charge to the stent portion is by means of an RF signal. By this method, the proximal end of the stent portion will be connected to a RF source.
It is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is understood that the following claims including all equivalents are intended to define the scope of the invention.

Claims

WE CLAIM:
1. A removable stent for temporarily supporting a region of a vessel in a body comprising: a stent portion comprised of: an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size.
2. The temporary stent of claim 1 in which said stent portion comprises: an elongate hollow tube having a proximal end and a distal end and further in which movement of said distal end toward said proximal end causes expansion of the diameter of said hollow tube and movement of said proximal end away from said distal end causes contraction of the diameter of the hollow tubular.
3. The temporary stent of claim 2 in which said actuator portion comprises: a first elongate member comprising an elongate catheter tube connected to said proximal end of said stent portion, and a second elongate member slidably disposed in a lumen of said first elongate member and extending to and operable to move said distal end of said stent portion with respect to said proximal end of said stent portion.
4. The stent of Claim 3 in which said elongate catheter tube comprises: an outer tubular layer, and an inner tubular layer concentric with said outer tubular layer.
5. The stent of Claim 4 in which a distal end of said inner tubular layer terminates proximally from the distal end of said outer tubular layer and further in which said outer tubular layer has a reduced diameter distally from the distal end of said inner tubular layer. member
6. The stent of Claim 1 in which said stent portion is comprised a plurality of helically wound wires forming an elongate hollow tube.
7. The stent of Claim 1 in which said stent portion is comprised a plurality of helically wound flat wires forming an elongate hollow tube in which the cross sectional dimension of the flat wires in the radial direction is less than the cross sectional dimension of the flat wires in the tangential direction.
8. The stent of Claim 6 in which said plurality of helically wound wires when said stent portion is in said expanded size comprise: a proximal tapered region connected to said first elongate member: and a distal tapered region connected to said second elongate member and further in which said plurality of helically wound wires forming the stent portion in said proximal tapered region and said distal tapered region are spaced apart from wires adjacent thereto to provide relatively large openings through said proximal and said distal tapered regions to facilitate blood flow therethrough.
9. The stent of Claim 6 in which said plurality of wires are comprised of stainless steel wires.
10 . The stent of Claim 1 in which said stent portion comprises at least in part a fluoroscopic detectable material.
11. The stent of Claim 10 in which said fluoroscopic detectable material is selected from a group consisting of: gold, tantalum, platinum, tungsten and tungsten-iridium alloy.
12. The stent of Claim 1 in which said second elongate member comprises: an inner catheter member having a lumen therewithin extending from a proximal end of said inner catheter member to an opening at the distal end of said inner catheter member.
13. The stent of Claim 12 in which said second inner catheter member is dimensioned so that fluids may be introduced to the distal end of said first elongate member via the lumen of said first elongate member in which said second catheter member is located.
14. The stent of Claim 3 in which said second elongate member further comprises: a guidewire tip extending distally from the distal end of said stent portion.
15. The stent of Claim 14 in which said second elongate member is connected to the distal end of said stent portion.
16. The stent of Claim 14 in which said second elongate member is slidingly received in the distal end of said stent portion and further in which said second elongate member comprises: a first bearing portion operable to move said distal end of said stent portion distally; and a second bearing portion operable to move said distal end of said stent portion proximally.
17. The stent of Claim 1 in which said actuator portion comprises at least in part a fluoroscopic detectable material.
18. The stent of Claim 17 further comprising: at least one band composed of a fluoroscopically detectable material connected to said actuator portion.
19. The stent of Claim 1 in which said stent portion is comprised at least in part of a material having non-thrombogenic properties.
20. The stent of Claim 19 in which said stent portion includes a coating of a material comprising a slow release non-thrombogenic polymer.
21. The stent of Claim 18 in which said coating is selected from a group consisting of urokinase, heparin, albumen protein and anti¬ thrombin III.
22. The stent of Claim 19 further comprising a DC source having a lead connected to said stent portion and another lead connectable to a patient's body.
23. A method of temporarily implanting a stent into a region of the vascular system of a patient comprising the steps of: advancing an expandable stent portion of the stent to the region, operating an actuator portion to cause expansion of the stent portion, supporting the region of the vascular system with the stent portion and allowing perfusion through the stent portion while in the stent portion is in an expanded configuration, operating an actuator portion to cause contraction of the stent portion, and withdrawing the stent portion.
24. The method of Claim 23 in which said step of operating an actuator portion to cause expansion of the stent portion further comprises: moving a proximal end of the stent portion relatively to a distal end of the stent portion to effect expansion of a diameter of the stent.
25. The method of Claim 24 in which the actuator comprises a first elongate member comprising an outer catheter member connected to a proximal end of the stent portion and a second elongate member connected to a distal end of the stent portion and further in which said operating steps comprise: moving a proximal end of the first elongate member with respect to a proximal end of the second elongate member.
26. The method of Claim 25 in which the second elongate member comprises an inner catheter member having a lumen therein and further comprising the steps of: positioning a guidewire in the vascular system of the patient to the region to be supported by the stent, advancing the stent portion, the outer catheter member, and the inner catheter member into the region of the vascular system over the guidewire through the lumen in the inner catheter member.
27. The method of Claim 26 further comprising the step of: introducing fluids to the vascular system via the lumen of the inner catheter member.
28. The method of Claim 26 further comprising the step of: introducing fluids to the vascular system via a lumen of the outer catheter member.
29. The method of Claim 23 further comprising the steps of: positioning a delivery catheter into the patient to the region of the vascular system of the patient; and advancing the stent portion and the actuator portion to the region of the vascular system through a lumen in the delivery catheter.
30. The method of Claim 23 further comprising the steps of: connecting a lead of a voltage source to the stent portion, connecting another lead to the body of the patient, and applying a potential between the leads to minimize the tendency for clotting materials to form on the stent portion.
31. The method of Claim 23 further comprising the steps of: connecting a lead of an RF source to the stent portion, and applying an RF signal to the lead to minimize the tendency for clotting materials to form on the stent portion.
32. A method for constructing a temporary stent to be used to support a region of the vascular system of a patient comprising the steps of: applying an ultralight tension on a braider carriage; braiding a plurality of wires into an elongate hollow tube; limiting the tent angle of the wires by means of a low friction guide;- fixing a proximal end of the braid between inner and outer concentric tubular layers; fixing a distal end of the braid to an inner catheter member, said inner catheter member located in and extending through a lumen formed by said inner and outer concentric tubular layers.
PCT/US1991/007570 1990-10-09 1991-10-09 Temporary stent and methods for use and manufacture WO1992005829A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4500711A JPH06502333A (en) 1990-10-09 1991-10-09 Temporary stent and its usage and manufacturing method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US594,121 1990-10-09
US07/594,121 US5222971A (en) 1990-10-09 1990-10-09 Temporary stent and methods for use and manufacture

Publications (1)

Publication Number Publication Date
WO1992005829A1 true WO1992005829A1 (en) 1992-04-16

Family

ID=24377609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/007570 WO1992005829A1 (en) 1990-10-09 1991-10-09 Temporary stent and methods for use and manufacture

Country Status (6)

Country Link
US (1) US5222971A (en)
EP (1) EP0552307A4 (en)
JP (1) JPH06502333A (en)
AU (1) AU9019391A (en)
CA (1) CA2091894A1 (en)
WO (1) WO1992005829A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605764A1 (en) * 1993-01-08 1994-07-13 Richard Wolf GmbH Device for implantation and extraction of stents
EP0634188A1 (en) * 1993-04-15 1995-01-18 BETA GROUP Inc An intra-luminal expander assembly
US5480423A (en) * 1993-05-20 1996-01-02 Boston Scientific Corporation Prosthesis delivery
EP0720838A1 (en) * 1995-01-03 1996-07-10 William Cook Europe A/S A method of manufaturing an assembly for positioning an ambolization coil in the vascular system, such an assembly and an assembly introducing apparatus
WO1998033454A1 (en) * 1997-01-31 1998-08-06 Ernst Peter Strecker Stent for treating pathological body vessels
WO2001030403A1 (en) * 1999-10-28 2001-05-03 Scimed Life Systems, Inc. Biocompatible medical devices
US6663606B1 (en) 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US6800073B2 (en) 1999-10-28 2004-10-05 Scimed Life Systems, Inc. Biocompatible pharmaceutical articles
WO2006119144A1 (en) 2005-05-04 2006-11-09 Wilson-Cook Medical Inc. Expandable and retrievable stent
US7955370B2 (en) 2004-08-06 2011-06-07 Boston Scientific Scimed, Inc. Stent delivery system
US8808272B2 (en) 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices

Families Citing this family (313)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782903A (en) * 1987-10-19 1998-07-21 Medtronic, Inc. Intravascular stent and method
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2380683C (en) 1991-10-28 2006-08-08 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5484449A (en) * 1992-01-07 1996-01-16 Medtronic, Inc. Temporary support for a body lumen and method
DE4240177C2 (en) * 1992-11-30 1997-02-13 Ruesch Willy Ag Self-expanding stent for hollow organs
US6576008B2 (en) * 1993-02-19 2003-06-10 Scimed Life Systems, Inc. Methods and device for inserting and withdrawing a two piece stent across a constricting anatomic structure
FR2701648B1 (en) 1993-02-19 1995-03-31 Marian Devonec Prosthesis intended for the treatment of a light or natural way, in particular endo-urethral prosthesis.
US5431676A (en) * 1993-03-05 1995-07-11 Innerdyne Medical, Inc. Trocar system having expandable port
US5843167A (en) * 1993-04-22 1998-12-01 C. R. Bard, Inc. Method and apparatus for recapture of hooked endoprosthesis
US5456667A (en) * 1993-05-20 1995-10-10 Advanced Cardiovascular Systems, Inc. Temporary stenting catheter with one-piece expandable segment
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
DE69419877T2 (en) * 1993-11-04 1999-12-16 Bard Inc C R Fixed vascular prosthesis
US5607444A (en) * 1993-12-02 1997-03-04 Advanced Cardiovascular Systems, Inc. Ostial stent for bifurcations
IT1269443B (en) * 1994-01-19 1997-04-01 Stefano Nazari VASCULAR PROSTHESIS FOR THE REPLACEMENT OR INTERNAL COATING OF MEDIUM AND LARGE DIAMETER BLOOD VESSELS AND DEVICE FOR ITS APPLICATION WITHOUT INTERRUPTION OF BLOOD FLOW
US6039749A (en) 1994-02-10 2000-03-21 Endovascular Systems, Inc. Method and apparatus for deploying non-circular stents and graftstent complexes
US5441516A (en) * 1994-03-03 1995-08-15 Scimed Lifesystems Inc. Temporary stent
DE69510986T2 (en) * 1994-04-25 1999-12-02 Advanced Cardiovascular System Radiation-opaque stent markings
DE9409484U1 (en) * 1994-06-11 1994-08-04 Naderlinger Eduard Vena cava thrombus filter
FR2722413B1 (en) * 1994-07-13 1997-02-07 Marian Devonec THERAPEUTIC IMPLANT INTENDED FOR THE SELECTIVE CYTOREDUCTIVE TREATMENT OF LIGHT OR NATURAL PATH OBSTRUCTION OF A HUMAN OR ANIMAL BODY
US5514176A (en) * 1995-01-20 1996-05-07 Vance Products Inc. Pull apart coil stent
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7846202B2 (en) * 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
WO1997014375A1 (en) * 1995-10-20 1997-04-24 Bandula Wijay Vascular stent
US5741293A (en) * 1995-11-28 1998-04-21 Wijay; Bandula Locking stent
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6203569B1 (en) 1996-01-04 2001-03-20 Bandula Wijay Flexible stent
DK0955950T3 (en) * 1996-01-04 2006-07-31 Timothy A M Dr Chuter Flat Wire Stent
US5725547A (en) * 1996-01-04 1998-03-10 Chuter; Timothy A. M. Corrugated stent
US6719782B1 (en) 1996-01-04 2004-04-13 Endovascular Technologies, Inc. Flat wire stent
US6258116B1 (en) 1996-01-26 2001-07-10 Cordis Corporation Bifurcated axially flexible stent
US5980553A (en) * 1996-12-20 1999-11-09 Cordis Corporation Axially flexible stent
US5895406A (en) * 1996-01-26 1999-04-20 Cordis Corporation Axially flexible stent
US5938682A (en) * 1996-01-26 1999-08-17 Cordis Corporation Axially flexible stent
NL1002423C2 (en) * 1996-02-22 1997-08-25 Cordis Europ Temporary filter catheter.
US5707387A (en) * 1996-03-25 1998-01-13 Wijay; Bandula Flexible stent
US5833699A (en) * 1996-04-10 1998-11-10 Chuter; Timothy A. M. Extending ribbon stent
US5951586A (en) * 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
US6077295A (en) 1996-07-15 2000-06-20 Advanced Cardiovascular Systems, Inc. Self-expanding stent delivery system
US6174329B1 (en) 1996-08-22 2001-01-16 Advanced Cardiovascular Systems, Inc. Protective coating for a stent with intermediate radiopaque coating
US8211167B2 (en) 1999-12-06 2012-07-03 Boston Scientific Scimed, Inc. Method of using a catheter with attached flexible side sheath
US7341598B2 (en) 1999-01-13 2008-03-11 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7591846B2 (en) 1996-11-04 2009-09-22 Boston Scientific Scimed, Inc. Methods for deploying stents in bifurcations
EP1723931B1 (en) 1996-11-04 2012-01-04 Advanced Stent Technologies, Inc. Extendible stent apparatus and method for deploying the same
US6835203B1 (en) 1996-11-04 2004-12-28 Advanced Stent Technologies, Inc. Extendible stent apparatus
US6692483B2 (en) 1996-11-04 2004-02-17 Advanced Stent Technologies, Inc. Catheter with attached flexible side sheath
US5860998A (en) * 1996-11-25 1999-01-19 C. R. Bard, Inc. Deployment device for tubular expandable prosthesis
EP1464302A3 (en) 1997-01-29 2010-09-22 Cook Incorporated Bell-bottom modular stent-graft
US6030415A (en) 1997-01-29 2000-02-29 Endovascular Technologies, Inc. Bell-bottom modular stent-graft
US6395021B1 (en) * 1997-02-26 2002-05-28 Applied Medical Resources Corporation Ureteral stent system apparatus and method
US6582472B2 (en) * 1997-02-26 2003-06-24 Applied Medical Resources Corporation Kinetic stent
US6026814A (en) * 1997-03-06 2000-02-22 Scimed Life Systems, Inc. System and method for percutaneous coronary artery bypass
US6155264A (en) * 1997-03-06 2000-12-05 Scimed Life Systems, Inc. Percutaneous bypass by tunneling through vessel wall
US6035856A (en) * 1997-03-06 2000-03-14 Scimed Life Systems Percutaneous bypass with branching vessel
US5902475A (en) 1997-04-08 1999-05-11 Interventional Technologies, Inc. Method for manufacturing a stent
US6726829B2 (en) 1997-04-08 2004-04-27 Scimed Life Systems, Inc. Method of manufacturing a stent
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US5891154A (en) * 1997-05-06 1999-04-06 Advanced Cardiovascular System, Inc. Passive perfusion stent delivery system
US6443158B1 (en) 1997-06-19 2002-09-03 Scimed Life Systems, Inc. Percutaneous coronary artery bypass through a venous vessel
US6092526A (en) * 1997-06-19 2000-07-25 Scimed Life Systems, Inc. Percutaneous chamber-to-artery bypass
US6213126B1 (en) 1997-06-19 2001-04-10 Scimed Life Systems, Inc. Percutaneous artery to artery bypass using heart tissue as a portion of a bypass conduit
JP3527619B2 (en) * 1997-06-25 2004-05-17 ペンタックス株式会社 Endoscope stent
US5891507A (en) * 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6070589A (en) 1997-08-01 2000-06-06 Teramed, Inc. Methods for deploying bypass graft stents
US5824059A (en) * 1997-08-05 1998-10-20 Wijay; Bandula Flexible stent
US7753950B2 (en) 1997-08-13 2010-07-13 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US6746476B1 (en) * 1997-09-22 2004-06-08 Cordis Corporation Bifurcated axially flexible stent
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6066149A (en) * 1997-09-30 2000-05-23 Target Therapeutics, Inc. Mechanical clot treatment device with distal filter
US7520890B2 (en) * 1998-01-26 2009-04-21 Phillips Peter W Reinforced graft and method of deployment
US6656215B1 (en) 2000-11-16 2003-12-02 Cordis Corporation Stent graft having an improved means for attaching a stent to a graft
US6290731B1 (en) 1998-03-30 2001-09-18 Cordis Corporation Aortic graft having a precursor gasket for repairing an abdominal aortic aneurysm
US6887268B2 (en) 1998-03-30 2005-05-03 Cordis Corporation Extension prosthesis for an arterial repair
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US6450989B2 (en) * 1998-04-27 2002-09-17 Artemis Medical, Inc. Dilating and support apparatus with disease inhibitors and methods for use
JP2002507930A (en) * 1998-04-27 2002-03-12 ドゥブルル,ウィリアム,アール Expandable support device with disease inhibitor and method of using same
US20100036481A1 (en) * 1998-04-27 2010-02-11 Artemis Medical, Inc. Cardiovascular Devices and Methods
US6171334B1 (en) 1998-06-17 2001-01-09 Advanced Cardiovascular Systems, Inc. Expandable stent and method of use
US6245052B1 (en) * 1998-07-08 2001-06-12 Innerdyne, Inc. Methods, systems, and kits for implanting articles
US6325824B2 (en) 1998-07-22 2001-12-04 Advanced Cardiovascular Systems, Inc. Crush resistant stent
US6461380B1 (en) 1998-07-28 2002-10-08 Advanced Cardiovascular Systems, Inc. Stent configuration
JP4187930B2 (en) 1998-08-03 2008-11-26 アンソン メディカル リミテッド Arterial repair device and method
US6325813B1 (en) 1998-08-18 2001-12-04 Scimed Life Systems, Inc. Method and apparatus for stabilizing vascular wall
US6117117A (en) * 1998-08-24 2000-09-12 Advanced Cardiovascular Systems, Inc. Bifurcated catheter assembly
US6117104A (en) * 1998-09-08 2000-09-12 Advanced Cardiovascular Systems, Inc. Stent deployment system and method of use
US6190403B1 (en) 1998-11-13 2001-02-20 Cordis Corporation Low profile radiopaque stent with increased longitudinal flexibility and radial rigidity
US6340366B2 (en) 1998-12-08 2002-01-22 Bandula Wijay Stent with nested or overlapping rings
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US7655030B2 (en) 2003-07-18 2010-02-02 Boston Scientific Scimed, Inc. Catheter balloon systems and methods
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
US6464723B1 (en) 1999-04-22 2002-10-15 Advanced Cardiovascular Systems, Inc. Radiopaque stents
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6375676B1 (en) 1999-05-17 2002-04-23 Advanced Cardiovascular Systems, Inc. Self-expanding stent with enhanced delivery precision and stent delivery system
US6884258B2 (en) 1999-06-04 2005-04-26 Advanced Stent Technologies, Inc. Bifurcation lesion stent delivery using multiple guidewires
US6458139B1 (en) 1999-06-21 2002-10-01 Endovascular Technologies, Inc. Filter/emboli extractor for use in variable sized blood vessels
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6540774B1 (en) 1999-08-31 2003-04-01 Advanced Cardiovascular Systems, Inc. Stent design with end rings having enhanced strength and radiopacity
US6585757B1 (en) 1999-09-15 2003-07-01 Advanced Cardiovascular Systems, Inc. Endovascular stent with radiopaque spine
US6602287B1 (en) 1999-12-08 2003-08-05 Advanced Cardiovascular Systems, Inc. Stent with anti-thrombogenic coating
US6443979B1 (en) 1999-12-20 2002-09-03 Advanced Cardiovascular Systems, Inc. Expandable stent delivery sheath and method of use
US6355058B1 (en) 1999-12-30 2002-03-12 Advanced Cardiovascular Systems, Inc. Stent with radiopaque coating consisting of particles in a binder
US6280465B1 (en) 1999-12-30 2001-08-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for delivering a self-expanding stent on a guide wire
US6471721B1 (en) 1999-12-30 2002-10-29 Advanced Cardiovascular Systems, Inc. Vascular stent having increased radiopacity and method for making same
US6537311B1 (en) 1999-12-30 2003-03-25 Advanced Cardiovascular Systems, Inc. Stent designs for use in peripheral vessels
US6942674B2 (en) * 2000-01-05 2005-09-13 Integrated Vascular Systems, Inc. Apparatus and methods for delivering a closure device
US6391048B1 (en) 2000-01-05 2002-05-21 Integrated Vascular Systems, Inc. Integrated vascular device with puncture site closure component and sealant and methods of use
GB2359024A (en) 2000-02-09 2001-08-15 Anson Medical Ltd Fixator for arteries
US6514273B1 (en) 2000-03-22 2003-02-04 Endovascular Technologies, Inc. Device for removal of thrombus through physiological adhesion
US6436132B1 (en) 2000-03-30 2002-08-20 Advanced Cardiovascular Systems, Inc. Composite intraluminal prostheses
GB2369575A (en) * 2000-04-20 2002-06-05 Salviac Ltd An embolic protection system
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6652579B1 (en) 2000-06-22 2003-11-25 Advanced Cardiovascular Systems, Inc. Radiopaque stent
US6540775B1 (en) 2000-06-30 2003-04-01 Cordis Corporation Ultraflexible open cell stent
JP2002200172A (en) * 2000-08-27 2002-07-16 Kazuyo Seko Medical tube and artificial organ preventing microbial infection and thrombosis
US6699278B2 (en) 2000-09-22 2004-03-02 Cordis Corporation Stent with optimal strength and radiopacity characteristics
US7499742B2 (en) 2001-09-26 2009-03-03 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US6850801B2 (en) 2001-09-26 2005-02-01 Cvrx, Inc. Mapping methods for cardiovascular reflex control devices
US7840271B2 (en) 2000-09-27 2010-11-23 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20080167699A1 (en) * 2000-09-27 2008-07-10 Cvrx, Inc. Method and Apparatus for Providing Complex Tissue Stimulation Parameters
US7616997B2 (en) 2000-09-27 2009-11-10 Kieval Robert S Devices and methods for cardiovascular reflex control via coupled electrodes
US6985774B2 (en) 2000-09-27 2006-01-10 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20080177348A1 (en) * 2000-09-27 2008-07-24 Cvrx, Inc. Electrode contact configurations for an implantable stimulator
US6522926B1 (en) 2000-09-27 2003-02-18 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US7158832B2 (en) * 2000-09-27 2007-01-02 Cvrx, Inc. Electrode designs and methods of use for cardiovascular reflex control devices
US8086314B1 (en) 2000-09-27 2011-12-27 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US7623926B2 (en) * 2000-09-27 2009-11-24 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
ATE343969T1 (en) 2000-09-29 2006-11-15 Cordis Corp COATED MEDICAL DEVICES
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6582394B1 (en) 2000-11-14 2003-06-24 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcated vessels
US7229472B2 (en) 2000-11-16 2007-06-12 Cordis Corporation Thoracic aneurysm repair prosthesis and system
US7314483B2 (en) 2000-11-16 2008-01-01 Cordis Corp. Stent graft with branch leg
US6942692B2 (en) 2000-11-16 2005-09-13 Cordis Corporation Supra-renal prosthesis and renal artery bypass
US6843802B1 (en) 2000-11-16 2005-01-18 Cordis Corporation Delivery apparatus for a self expanding retractable stent
US7267685B2 (en) 2000-11-16 2007-09-11 Cordis Corporation Bilateral extension prosthesis and method of delivery
US7905900B2 (en) 2003-01-30 2011-03-15 Integrated Vascular Systems, Inc. Clip applier and methods of use
US6540733B2 (en) 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
DE60237884D1 (en) * 2001-01-23 2010-11-18 Abbeymoor Medical Inc END EUROPEAN DEVICE
US6679911B2 (en) 2001-03-01 2004-01-20 Cordis Corporation Flexible stent
US6790227B2 (en) * 2001-03-01 2004-09-14 Cordis Corporation Flexible stent
US6740114B2 (en) 2001-03-01 2004-05-25 Cordis Corporation Flexible stent
AU784552B2 (en) * 2001-03-02 2006-05-04 Cardinal Health 529, Llc Flexible stent
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
US7011675B2 (en) * 2001-04-30 2006-03-14 Boston Scientific Scimed, Inc. Endoscopic stent delivery system and method
US8182527B2 (en) * 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US8617231B2 (en) * 2001-05-18 2013-12-31 Boston Scientific Scimed, Inc. Dual guidewire exchange catheter system
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
DE60237899D1 (en) 2001-08-01 2010-11-18 Tyco Healthcare DEVICE FOR OBTAINING PERCUTANEOUS ACCESS TO AND PROVIDING A MEDICAMENT AT AN OPERATING DESTINATION
US7252679B2 (en) * 2001-09-13 2007-08-07 Cordis Corporation Stent with angulated struts
US6790223B2 (en) 2001-09-21 2004-09-14 Scimed Life Systems, Inc. Delivering a uretheral stent
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
CA2464053A1 (en) * 2001-11-09 2003-05-22 Novoste Corporation Baloon catheter with non-deployable stent
US20040111108A1 (en) * 2001-11-09 2004-06-10 Farnan Robert C. Balloon catheter with non-deployable stent
US7326237B2 (en) 2002-01-08 2008-02-05 Cordis Corporation Supra-renal anchoring prosthesis
US7029493B2 (en) * 2002-01-25 2006-04-18 Cordis Corporation Stent with enhanced crossability
US7519418B2 (en) * 2002-04-30 2009-04-14 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US7329268B2 (en) * 2002-07-02 2008-02-12 Warsaw Orthopedic, Inc. Expandable percutaneous sheath
ATE495769T1 (en) 2002-07-12 2011-02-15 Cook Inc COATED MEDICAL DEVICE
DE10233085B4 (en) 2002-07-19 2014-02-20 Dendron Gmbh Stent with guide wire
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
EP1592367B1 (en) 2002-08-28 2016-04-13 HLT, Inc. Method and device for treating diseased valve
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
US20040148016A1 (en) * 2002-11-07 2004-07-29 Klein Dean A. Biocompatible medical device coatings
AU2003295878B2 (en) * 2002-11-22 2008-07-10 Covidien Lp Sheath introduction apparatus and method
US8080026B2 (en) 2003-01-21 2011-12-20 Angioscore, Inc. Apparatus and methods for treating hardened vascular lesions
US8398656B2 (en) 2003-01-30 2013-03-19 Integrated Vascular Systems, Inc. Clip applier and methods of use
US20060111626A1 (en) * 2003-03-27 2006-05-25 Cvrx, Inc. Electrode structures having anti-inflammatory properties and methods of use
US7651529B2 (en) * 2003-05-09 2010-01-26 Boston Scientific Scimed, Inc. Stricture retractor
AU2004243014B2 (en) 2003-05-23 2009-12-10 Boston Scientific Limited Stents with attached looped ends
US8298280B2 (en) 2003-08-21 2012-10-30 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7479150B2 (en) * 2003-09-19 2009-01-20 Tyco Healthcare Group Lp Trocar insertion apparatus
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7480532B2 (en) * 2003-10-22 2009-01-20 Cvrx, Inc. Baroreflex activation for pain control, sedation and sleep
US7344557B2 (en) 2003-11-12 2008-03-18 Advanced Stent Technologies, Inc. Catheter balloon systems and methods
US20050125050A1 (en) * 2003-12-04 2005-06-09 Wilson Cook Medical Incorporated Biliary stent introducer system
US9241735B2 (en) 2003-12-05 2016-01-26 Onset Medical Corporation Expandable percutaneous sheath
US7780692B2 (en) * 2003-12-05 2010-08-24 Onset Medical Corporation Expandable percutaneous sheath
US7258697B1 (en) 2003-12-22 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent with anchors to prevent vulnerable plaque rupture during deployment
WO2005096994A1 (en) * 2004-03-31 2005-10-20 Wilson-Cook Medical Inc. Stent introducer system
US20060041270A1 (en) * 2004-05-07 2006-02-23 Jay Lenker Medical access sheath
US8267985B2 (en) 2005-05-25 2012-09-18 Tyco Healthcare Group Lp System and method for delivering and deploying an occluding device within a vessel
US20060004417A1 (en) * 2004-06-30 2006-01-05 Cvrx, Inc. Baroreflex activation for arrhythmia treatment
US7892203B2 (en) 2004-09-09 2011-02-22 Onset Medical Corporation Expandable transluminal sheath
US20060135962A1 (en) * 2004-09-09 2006-06-22 Kick George F Expandable trans-septal sheath
WO2006031619A2 (en) 2004-09-09 2006-03-23 Onset Medical Corporation Expandable transluminal sheath
US20060074483A1 (en) * 2004-10-01 2006-04-06 Schrayer Howard L Method of treatment and devices for the treatment of left ventricular failure
US8337543B2 (en) 2004-11-05 2012-12-25 Boston Scientific Scimed, Inc. Prosthesis anchoring and deploying device
WO2006069396A1 (en) * 2004-12-21 2006-06-29 Onset Medical Corporation Non-expandable transluminal access sheath
US8057543B2 (en) * 2005-01-28 2011-11-15 Greatbatch Ltd. Stent coating for eluting medication
US20090132021A1 (en) * 2005-02-01 2009-05-21 Shifrin Edward G Apparatus and method for delivery, spreading and double-ended fixation of vascular grafts
US20060212062A1 (en) * 2005-03-16 2006-09-21 David Farascioni Radially expandable access system including trocar seal
US7955345B2 (en) * 2005-04-01 2011-06-07 Nexgen Medical Systems, Inc. Thrombus removal system and process
US7955344B2 (en) * 2005-04-01 2011-06-07 Nexgen Medical Systems, Inc. Thrombus removal system and process
US7947207B2 (en) 2005-04-12 2011-05-24 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US7763198B2 (en) 2005-04-12 2010-07-27 Abbott Cardiovascular Systems Inc. Method for retaining a vascular stent on a catheter
US20060259061A1 (en) * 2005-04-22 2006-11-16 Kick George F Expandable sheath for percutaneous upper gastrointestinal tract access
EP1903999B1 (en) 2005-04-25 2018-11-21 Covidien LP Controlled fracture connections for stents
US10076641B2 (en) 2005-05-11 2018-09-18 The Spectranetics Corporation Methods and systems for delivering substances into luminal walls
US8273101B2 (en) 2005-05-25 2012-09-25 Tyco Healthcare Group Lp System and method for delivering and deploying an occluding device within a vessel
JP4945714B2 (en) 2005-05-25 2012-06-06 タイコ ヘルスケア グループ リミテッド パートナーシップ System and method for supplying and deploying an occlusion device in a conduit
US8092481B2 (en) * 2005-06-03 2012-01-10 Onset Medical Corporation Expandable percutaneous sheath
US8313497B2 (en) 2005-07-01 2012-11-20 Abbott Laboratories Clip applier and methods of use
JP3816092B1 (en) * 2005-08-03 2006-08-30 ベクトル株式会社 Ureteral stent
US20100152523A1 (en) * 2005-11-28 2010-06-17 Myocardiocare, Inc. Method and Apparatus for Minimally Invasive Direct Mechanical Ventricular Actuation
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8109879B2 (en) * 2006-01-10 2012-02-07 Cardiac Pacemakers, Inc. Assessing autonomic activity using baroreflex analysis
AU2007211269B2 (en) 2006-02-01 2013-10-03 The Cleveland Clinic Foundation A method and apparatus for increasing blood flow through an obstructed blood vessel
US8821561B2 (en) 2006-02-22 2014-09-02 Boston Scientific Scimed, Inc. Marker arrangement for bifurcation catheter
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
AU2007299934B2 (en) * 2006-09-28 2013-09-12 Hlt, Inc. Delivery tool for percutaneous delivery of a prosthesis
US8647349B2 (en) 2006-10-18 2014-02-11 Hologic, Inc. Systems for performing gynecological procedures with mechanical distension
US20080269774A1 (en) 2006-10-26 2008-10-30 Chestnut Medical Technologies, Inc. Intracorporeal Grasping Device
US8025656B2 (en) * 2006-11-07 2011-09-27 Hologic, Inc. Methods, systems and devices for performing gynecological procedures
US9392935B2 (en) * 2006-11-07 2016-07-19 Hologic, Inc. Methods for performing a medical procedure
WO2008079828A2 (en) 2006-12-20 2008-07-03 Onset Medical Corporation Expandable trans-septal sheath
AU2008209480A1 (en) 2007-01-22 2008-07-31 California Institute Of Technology Method for quantitative 3-D imaging
US8249705B1 (en) 2007-03-20 2012-08-21 Cvrx, Inc. Devices, systems, and methods for improving left ventricular structure and function using baroreflex activation therapy
US20090270898A1 (en) * 2007-04-06 2009-10-29 Interlace Medical, Inc. Tissue removal device with high reciprocation rate
US9095366B2 (en) 2007-04-06 2015-08-04 Hologic, Inc. Tissue cutter with differential hardness
EP2134283B1 (en) 2007-04-06 2014-06-11 Hologic, Inc. System and device for tissue removal
US9259233B2 (en) 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
KR20100017235A (en) 2007-04-23 2010-02-16 캘리포니아 인스티튜트 오브 테크놀로지 An aperture system with spatially-biased aperture for defocusing-based imaging
US20090132002A1 (en) * 2007-05-11 2009-05-21 Cvrx, Inc. Baroreflex activation therapy with conditional shut off
US9364586B2 (en) 2007-05-31 2016-06-14 Abbott Cardiovascular Systems Inc. Method and apparatus for improving delivery of an agent to a kidney
US9149610B2 (en) 2007-05-31 2015-10-06 Abbott Cardiovascular Systems Inc. Method and apparatus for improving delivery of an agent to a kidney
US9144509B2 (en) 2007-05-31 2015-09-29 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8594794B2 (en) 2007-07-24 2013-11-26 Cvrx, Inc. Baroreflex activation therapy with incrementally changing intensity
US20090043380A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8795326B2 (en) 2007-10-05 2014-08-05 Covidien Lp Expanding seal anchor for single incision surgery
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
US9198687B2 (en) 2007-10-17 2015-12-01 Covidien Lp Acute stroke revascularization/recanalization systems processes and products thereby
US8926680B2 (en) 2007-11-12 2015-01-06 Covidien Lp Aneurysm neck bridging processes with revascularization systems methods and products thereby
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US8545514B2 (en) 2008-04-11 2013-10-01 Covidien Lp Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby
US8066757B2 (en) 2007-10-17 2011-11-29 Mindframe, Inc. Blood flow restoration and thrombus management methods
US9220522B2 (en) 2007-10-17 2015-12-29 Covidien Lp Embolus removal systems with baskets
US8585713B2 (en) 2007-10-17 2013-11-19 Covidien Lp Expandable tip assembly for thrombus management
US10123803B2 (en) 2007-10-17 2018-11-13 Covidien Lp Methods of managing neurovascular obstructions
US8893947B2 (en) 2007-12-17 2014-11-25 Abbott Laboratories Clip applier and methods of use
WO2009088953A2 (en) 2007-12-31 2009-07-16 Boston Scientific Scimed Inc. Bifurcation stent delivery system and methods
ES2647310T3 (en) 2008-02-22 2017-12-20 Covidien Lp Device for flow restoration
EP3970633A1 (en) 2008-04-21 2022-03-23 Covidien LP Braid-ball embolic devices and delivery systems
US9675482B2 (en) 2008-05-13 2017-06-13 Covidien Lp Braid implant delivery systems
US9282965B2 (en) 2008-05-16 2016-03-15 Abbott Laboratories Apparatus and methods for engaging tissue
US8377108B2 (en) 2008-06-02 2013-02-19 Boston Scientific Scimed, Inc. Staggered two balloon bifurcation catheter assembly and methods
WO2009149410A1 (en) 2008-06-05 2009-12-10 Boston Scientific Scimed, Inc. Deflatable bifurcated device
EP2299945B1 (en) 2008-06-05 2016-03-23 Boston Scientific Scimed, Inc. Balloon bifurcated lumen treatment
CN102137626A (en) 2008-07-22 2011-07-27 微治疗公司 Vascular remodeling device
AU2009279386A1 (en) * 2008-08-08 2010-02-11 Osprey Medical Inc. Reverse catheter
EP2428932A1 (en) 2008-08-27 2012-03-14 California Institute of Technology Method and device for high-resolution three-dimensional imaging which obtains camera pose using defocusing
US9486191B2 (en) 2009-01-09 2016-11-08 Abbott Vascular, Inc. Closure devices
US11903602B2 (en) 2009-04-29 2024-02-20 Hologic, Inc. Uterine fibroid tissue removal device
US8773507B2 (en) 2009-08-11 2014-07-08 California Institute Of Technology Defocusing feature matching system to measure camera pose with interchangeable lens cameras
US20110202085A1 (en) 2009-11-09 2011-08-18 Siddharth Loganathan Braid Ball Embolic Device Features
EP2528541B1 (en) 2010-01-28 2016-05-18 Covidien LP Vascular remodeling device
CN102740799A (en) 2010-01-28 2012-10-17 泰科保健集团有限合伙公司 Vascular remodeling device
US20110196189A1 (en) * 2010-02-09 2011-08-11 Myocardiocare, Inc. Extra-cardiac differential ventricular actuation by inertial and baric partitioning
US20110196478A1 (en) * 2010-02-10 2011-08-11 Beoptima Inc. Devices and methods for lumen treatment
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
EP2380604A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved coating formulations for scoring or cutting balloon catheters
US9144455B2 (en) 2010-06-07 2015-09-29 Just Right Surgical, Llc Low power tissue sealing device and method
DK2612297T3 (en) 2010-09-03 2017-11-13 California Inst Of Techn THREE-DIMENSIONAL IMAGE SYSTEM
US8632559B2 (en) 2010-09-21 2014-01-21 Angioscore, Inc. Method and system for treating valve stenosis
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
US9039750B2 (en) * 2010-12-16 2015-05-26 Cook Medical Technologies Llc Handle control system for a stent delivery system
AU2012214240B2 (en) 2011-02-11 2015-03-12 Covidien Lp Two-stage deployment aneurysm embolization devices
US20120310210A1 (en) 2011-03-04 2012-12-06 Campbell Carey V Eluting medical devices
US9415193B2 (en) 2011-03-04 2016-08-16 W. L. Gore & Associates, Inc. Eluting medical devices
US20120245674A1 (en) 2011-03-25 2012-09-27 Tyco Healthcare Group Lp Vascular remodeling device
US9101507B2 (en) 2011-05-18 2015-08-11 Ralph F. Caselnova Apparatus and method for proximal-to-distal endoluminal stent deployment
WO2013049448A1 (en) 2011-09-29 2013-04-04 Covidien Lp Vascular remodeling device
KR20140114856A (en) 2012-02-01 2014-09-29 콰트로 배스큘러 피티이 리미티드 Device for compartmental dilatation of blood vessels
US9179936B2 (en) 2012-02-08 2015-11-10 Quattro Vascular Pte Ltd. Constraining structure with non-linear axial struts
US9216033B2 (en) 2012-02-08 2015-12-22 Quattro Vascular Pte Ltd. System and method for treating biological vessels
US9155647B2 (en) 2012-07-18 2015-10-13 Covidien Lp Methods and apparatus for luminal stenting
US9901715B2 (en) 2012-09-05 2018-02-27 W. L. Gore Associates, Inc. Retractable sheath devices, systems, and methods
US9314248B2 (en) 2012-11-06 2016-04-19 Covidien Lp Multi-pivot thrombectomy device
US9364209B2 (en) 2012-12-21 2016-06-14 Abbott Cardiovascular Systems, Inc. Articulating suturing device
US9295571B2 (en) 2013-01-17 2016-03-29 Covidien Lp Methods and apparatus for luminal stenting
US9463105B2 (en) 2013-03-14 2016-10-11 Covidien Lp Methods and apparatus for luminal stenting
CN105142545B (en) 2013-03-15 2018-04-06 柯惠有限合伙公司 Locking device
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
US10117668B2 (en) 2013-10-08 2018-11-06 The Spectranetics Corporation Balloon catheter with non-deployable stent having improved stability
US10232148B2 (en) 2014-11-17 2019-03-19 TriReme Medical, LLC Balloon catheter system and method of using same
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
US11141177B2 (en) 2015-11-30 2021-10-12 Piranha Medical Llc Blockage clearing devices, systems, and methods
US11406264B2 (en) 2016-01-25 2022-08-09 California Institute Of Technology Non-invasive measurement of intraocular pressure
US10130465B2 (en) 2016-02-23 2018-11-20 Abbott Cardiovascular Systems Inc. Bifurcated tubular graft for treating tricuspid regurgitation
CN109475418A (en) 2016-07-13 2019-03-15 波士顿科学国际有限公司 For the instrument and method in the intravascular maintenance smoothness adjacent with nearby performing the operation
US10575973B2 (en) 2018-04-11 2020-03-03 Abbott Cardiovascular Systems Inc. Intravascular stent having high fatigue performance
USD904611S1 (en) 2018-10-10 2020-12-08 Bolder Surgical, Llc Jaw design for a surgical instrument
US11090174B1 (en) * 2020-02-11 2021-08-17 Amaitus, Inc. Temporary and retrievable expandable member

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871357A (en) * 1986-01-21 1989-10-03 Baxter International Inc. Ionic heparin coating
US4998539A (en) * 1987-12-18 1991-03-12 Delsanti Gerard L Method of using removable endo-arterial devices to repair detachments in the arterial walls
US5002560A (en) * 1989-09-08 1991-03-26 Advanced Cardiovascular Systems, Inc. Expandable cage catheter with a rotatable guide

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836181A (en) * 1955-01-17 1958-05-27 Chemstrand Corp Flexible nylon tube and method for preparing same
US3320957A (en) * 1964-05-21 1967-05-23 Sokolik Edward Surgical instrument
US3509883A (en) * 1967-11-29 1970-05-05 Gen Electric Expanding cannula
US3663288A (en) * 1969-09-04 1972-05-16 American Cyanamid Co Physiologically acceptible elastomeric article
US3868956A (en) * 1972-06-05 1975-03-04 Ralph J Alfidi Vessel implantable appliance and method of implanting it
US3996938A (en) * 1975-07-10 1976-12-14 Clark Iii William T Expanding mesh catheter
US4046150A (en) * 1975-07-17 1977-09-06 American Hospital Supply Corporation Medical instrument for locating and removing occlusive objects
US4140126A (en) * 1977-02-18 1979-02-20 Choudhury M Hasan Method for performing aneurysm repair
DE2821048C2 (en) * 1978-05-13 1980-07-17 Willy Ruesch Gmbh & Co Kg, 7053 Kernen Medical instrument
SE424045B (en) * 1979-01-12 1982-06-28 Tesi Ab CATHETER
US4307722A (en) * 1979-08-14 1981-12-29 Evans Joseph M Dilators for arterial dilation
IT1126526B (en) * 1979-12-07 1986-05-21 Enrico Dormia SURGICAL EXTRACTOR TO REMOVE FOREIGN BODIES THAT ARE FOUND IN THE NATURAL ROUTES OF THE HUMAN BODY, AS CALCULATIONS AND SIMILAR
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
DE3107392A1 (en) * 1981-02-27 1982-09-16 Willy Rüsch GmbH & Co KG, 7053 Kernen Medical instrument
DE3250058C2 (en) * 1981-09-16 1992-08-27 Medinvent S.A., Lausanne, Ch
SE445884B (en) * 1982-04-30 1986-07-28 Medinvent Sa DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION
US4512338A (en) * 1983-01-25 1985-04-23 Balko Alexander B Process for restoring patency to body vessels
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4656083A (en) * 1983-08-01 1987-04-07 Washington Research Foundation Plasma gas discharge treatment for improving the biocompatibility of biomaterials
US4572186A (en) * 1983-12-07 1986-02-25 Cordis Corporation Vessel dilation
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4629458A (en) * 1985-02-26 1986-12-16 Cordis Corporation Reinforcing structure for cardiovascular graft
US4713402A (en) * 1985-08-30 1987-12-15 Becton, Dickinson And Company Process for preparing antithrombogenic/antibiotic polymeric plastic materials
DE3532653C2 (en) * 1985-09-13 1993-10-21 Martin Kaltenbach Dilatation catheter
US4650466A (en) * 1985-11-01 1987-03-17 Angiobrade Partners Angioplasty device
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4649922A (en) * 1986-01-23 1987-03-17 Wiktor Donimik M Catheter arrangement having a variable diameter tip and spring prosthesis
EP0257091B1 (en) * 1986-02-24 1993-07-28 Robert E. Fischell An intravascular stent and percutaneous insertion system
US4878906A (en) * 1986-03-25 1989-11-07 Servetus Partnership Endoprosthesis for repairing a damaged vessel
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US4723549A (en) * 1986-09-18 1988-02-09 Wholey Mark H Method and apparatus for dilating blood vessels
US4773432A (en) * 1987-02-09 1988-09-27 Schneider-Shiley (Usa) Inc. Bail-out catheter
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4795458A (en) * 1987-07-02 1989-01-03 Regan Barrie F Stent for use following balloon angioplasty
DE3855725T2 (en) * 1987-10-08 1997-04-17 Terumo Corp INSTRUMENT AND DEVICE FOR MAINTAINING THE INNER LUMEN DIAMETER OF A TUBULAR ORGAN
US4819751A (en) * 1987-10-16 1989-04-11 Baxter Travenol Laboratories, Inc. Valvuloplasty catheter and method
US4820298A (en) * 1987-11-20 1989-04-11 Leveen Eric G Internal vascular prosthesis
US4986831A (en) * 1988-04-25 1991-01-22 Angeion Corporation Medical implant
US4921484A (en) * 1988-07-25 1990-05-01 Cordis Corporation Mesh balloon catheter device
US4885003A (en) * 1988-07-25 1989-12-05 Cordis Corporation Double mesh balloon catheter device
US4913141A (en) * 1988-10-25 1990-04-03 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US4950227A (en) * 1988-11-07 1990-08-21 Boston Scientific Corporation Stent delivery system
US4856516A (en) * 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
CH678393A5 (en) * 1989-01-26 1991-09-13 Ulrich Prof Dr Med Sigwart
US5059169A (en) * 1989-07-07 1991-10-22 C. R. Bard, Inc. High-friction prostatic stent
EP0408245B1 (en) * 1989-07-13 1994-03-02 American Medical Systems, Inc. Stent placement instrument
US5034001A (en) * 1989-09-08 1991-07-23 Advanced Cardiovascular Systems, Inc. Method of repairing a damaged blood vessel with an expandable cage catheter
US5180368A (en) * 1989-09-08 1993-01-19 Advanced Cardiovascular Systems, Inc. Rapidly exchangeable and expandable cage catheter for repairing damaged blood vessels
US5059166A (en) * 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871357A (en) * 1986-01-21 1989-10-03 Baxter International Inc. Ionic heparin coating
US4998539A (en) * 1987-12-18 1991-03-12 Delsanti Gerard L Method of using removable endo-arterial devices to repair detachments in the arterial walls
US5002560A (en) * 1989-09-08 1991-03-26 Advanced Cardiovascular Systems, Inc. Expandable cage catheter with a rotatable guide

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605764A1 (en) * 1993-01-08 1994-07-13 Richard Wolf GmbH Device for implantation and extraction of stents
US5411507A (en) * 1993-01-08 1995-05-02 Richard Wolf Gmbh Instrument for implanting and extracting stents
EP0634188A1 (en) * 1993-04-15 1995-01-18 BETA GROUP Inc An intra-luminal expander assembly
US5480423A (en) * 1993-05-20 1996-01-02 Boston Scientific Corporation Prosthesis delivery
EP0720838A1 (en) * 1995-01-03 1996-07-10 William Cook Europe A/S A method of manufaturing an assembly for positioning an ambolization coil in the vascular system, such an assembly and an assembly introducing apparatus
US5725534A (en) * 1995-01-03 1998-03-10 William Cook Europe A/S Method of manufacturing an assembly for positioning an embolization coil in the vascular system, and such an assembly
US6485524B2 (en) 1997-01-31 2002-11-26 Ernst-Peter Strecker Stent for treating pathological body vessels
WO1998033454A1 (en) * 1997-01-31 1998-08-06 Ernst Peter Strecker Stent for treating pathological body vessels
WO2001030403A1 (en) * 1999-10-28 2001-05-03 Scimed Life Systems, Inc. Biocompatible medical devices
US6638259B1 (en) 1999-10-28 2003-10-28 Scimed Life Systems, Inc. Biocompatible medical devices
US6663606B1 (en) 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US6800073B2 (en) 1999-10-28 2004-10-05 Scimed Life Systems, Inc. Biocompatible pharmaceutical articles
EP1658862A1 (en) * 1999-10-28 2006-05-24 Boston Scientific Limited Biocompatible medical devices
US7060056B2 (en) 1999-10-28 2006-06-13 Boston Scientific Scimed, Inc. Biocompatible pharmaceutical articles
US8808272B2 (en) 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices
US7955370B2 (en) 2004-08-06 2011-06-07 Boston Scientific Scimed, Inc. Stent delivery system
WO2006119144A1 (en) 2005-05-04 2006-11-09 Wilson-Cook Medical Inc. Expandable and retrievable stent
US7727270B2 (en) 2005-05-04 2010-06-01 Wilson Cook Medical Inc Expandable and retrievable stent
AU2006242378B2 (en) * 2005-05-04 2011-07-07 Cook Medical Technologies Llc Expandable and retrievable stent

Also Published As

Publication number Publication date
CA2091894A1 (en) 1992-04-10
US5222971A (en) 1993-06-29
JPH06502333A (en) 1994-03-17
AU9019391A (en) 1992-04-28
EP0552307A1 (en) 1993-07-28
EP0552307A4 (en) 1993-10-13

Similar Documents

Publication Publication Date Title
US5222971A (en) Temporary stent and methods for use and manufacture
US5449372A (en) Temporary stent and methods for use and manufacture
JP6793147B2 (en) Devices and methods for treating aneurysms
US5695469A (en) Vascular dilatation device and method
EP0257091B1 (en) An intravascular stent and percutaneous insertion system
US7419503B2 (en) Stent
US6010530A (en) Self-expanding endoluminal prosthesis
EP1755485B1 (en) Method and system for stent retention using an adhesive
US20030055377A1 (en) Exchangeable catheter
EP1470798A2 (en) Method and system for stent retention using an adhesive
WO2008094504A1 (en) Medical prosthesis and method of production
JP2001513359A (en) Microporous stent and implant device
JPH0833719A (en) Lumen organs medical treatment tool
EP1265651B1 (en) Selective radiopaque plating of a stent
US9572650B2 (en) Embolic protection devices having short landing zones
EP1390095A2 (en) Exchangeable catheter
JP4181354B2 (en) Medical equipment
CN114504718A (en) Transcranial radial artery intracranial catheter
US20060079951A1 (en) Guide catheter with attached stent delivery system
CA1274740A (en) Intravascular stent and percutaneous catheter system
JP3576626B2 (en) Stent transport indwelling device
JPH07289646A (en) Tubular organ therapeutic implement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KR LK LU MC MG MW NL NO PL RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2091894

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991920909

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991920909

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1991920909

Country of ref document: EP